{"gene":"ASCL1","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":2006,"finding":"Ascl1 controls excitatory vs. inhibitory cell fate in spinal sensory interneurons by coordinately regulating Tlx3 expression (with Gsh1/2) during early neurogenesis and, at later stages, controlling Ptf1a expression in dIL(A) progenitors to promote inhibitory neuron differentiation while upregulating Notch signaling to ensure generation of dIL(B) excitatory neurons.","method":"Mouse genetic loss-of-function (Ascl1 knockout), genetic epistasis, in vivo analysis of transcription factor expression","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined cellular phenotype, epistasis analysis, replicated across multiple developmental time points in vivo","pmids":["16715081"],"is_preprint":false},{"year":2004,"finding":"Ascl1 is required for the birth of central serotonergic neurons, functioning both as a proneural gene for the production of postmitotic neuronal precursors and as a determinant of the serotonergic phenotype by activating Gata3, Lmx1b, and Pet1 in parallel.","method":"Mouse Ascl1 knockout, analysis of 5-HT neuron production and serotonergic marker expression in vivo","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined cellular and molecular phenotype, multiple downstream targets characterized","pmids":["15133515"],"is_preprint":false},{"year":2006,"finding":"Ascl1 marks sequentially generated lineage-restricted progenitors in the developing spinal cord: at E11 it identifies neuronal-restricted precursors that become dorsal horn neurons, and by E16 it identifies oligodendrocyte-restricted precursors. Ascl1-null spinal cord cells have diminished capacity for neuronal differentiation, with a subset retaining immature glial characteristics.","method":"Genetic fate mapping (Ascl1-CreER / conditional Cre-flox), Ascl1 knockout mouse, temporal inducible lineage tracing","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic fate mapping plus KO with defined cellular phenotypes across multiple time points","pmids":["17166924"],"is_preprint":false},{"year":2008,"finding":"Ascl1 is required for oligodendrocyte development in the spinal cord: Ascl1-/- mice show deficiency in myelin-expressing oligodendrocyte differentiation; Ascl1 collaborates with Olig2 and Nkx2-2 to promote oligodendrocyte precursor differentiation, with the combinatorial action of Ascl1+Olig2 or Ascl1+Nkx2-2 required for full differentiation beyond OLP specification.","method":"Ascl1 knockout mouse, in vitro OLP culture studies, gain-of-function overexpression of Ascl1/Olig2/Nkx2-2 combinations","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO phenotype combined with gain-of-function and combinatorial factor analysis with defined molecular readouts","pmids":["18287202"],"is_preprint":false},{"year":2009,"finding":"Ascl1 regulates Delta-like 3 (Dll3) expression in the neural tube by binding E-boxes in the conserved Dll3 proximal promoter. Distinct E-boxes confer enhancer or repressor properties; Ascl1 forms homodimers and Ascl1/Neurog2 heterodimers that bind specific E-box sites, sometimes requiring additional undefined factors for efficient DNA binding.","method":"Transgenic reporter mice (Dll3-GFP), E-box mutagenesis, chromatin immunoprecipitation (ChIP), in vitro DNA binding assays, genetic loss-of-function","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro DNA binding with mutagenesis, ChIP, transgenic reporter validation, and genetic KO, single lab but multiple orthogonal methods","pmids":["19389376"],"is_preprint":false},{"year":2011,"finding":"Ascl1 is present in progenitors of all glial and neuronal cell types arising from the cerebellar ventricular zone. Conditional deletion of Ascl1 in the cerebellum causes major decreases in three types of GABAergic interneurons and an imbalance of oligodendrocytes and astrocytes; Ptf1a functions with Ascl1 in generating interneurons and Purkinje cells (double-mutant epistasis).","method":"Genetic inducible fate mapping (Ascl1-CreER), conditional Ascl1 knockout, double-mutant (Ascl1/Ptf1a) analysis","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — fate mapping plus conditional KO plus epistasis analysis with defined cellular phenotypes","pmids":["21795554"],"is_preprint":false},{"year":2013,"finding":"FOXO3 shares common genomic targets with ASCL1 in adult neural progenitor cells (NPCs); FOXO3-bound sites are enriched for bHLH motifs; FOXO3 inhibits ASCL1-dependent neurogenesis in NPCs and direct neuronal conversion in fibroblasts, and restrains neurogenesis in vivo.","method":"ChIP-seq (FOXO3 and ASCL1), chromatin landscape analysis, loss-of-function neurogenesis assays in NPCs and fibroblasts, in vivo neurogenesis assay","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genome-wide ChIP-seq for both factors plus functional KD/OE assays in vitro and in vivo, single lab with multiple orthogonal methods","pmids":["23891001"],"is_preprint":false},{"year":2013,"finding":"Ascl1 is required for brain oligodendrogenesis during myelination and remyelination: Ascl1 positively regulates OPC specification from SVZ progenitors and the balance between OPC differentiation and proliferation in the neonatal cortex; remyelinating oligodendrocytes derive from Ascl1+ progenitors and Ascl1 is required for proper remyelination.","method":"Multiple genetic Ascl1 deletion strategies in cortical progenitors and OPCs, demyelination mouse models, analysis of human MS lesions","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic deletion approaches, in vivo demyelination model, and human tissue validation","pmids":["23739972"],"is_preprint":false},{"year":2014,"finding":"ASCL1 alone is sufficient to generate functional induced neuronal (iN) cells from mouse and human fibroblasts and embryonic stem cells; ASCL1-induced single-factor neurons are predominantly excitatory, demonstrating ASCL1 is permissive but not deterministic for the inhibitory neuronal lineage.","method":"Forced expression of single transcription factor ASCL1 in MEFs and human fibroblasts/ESCs; electrophysiology, synaptic marker analysis, neuronal morphology assessment","journal":"Stem cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional reprogramming in multiple cell types with electrophysiological validation and synaptic characterization","pmids":["25254342"],"is_preprint":false},{"year":2014,"finding":"ASCL1 directly transcriptionally activates the RB1 gene via phosphorylation-dependent inactivation; this is reversible by CDK5 inhibition. ASCL1 targets include MYCL1, RET, SOX2, NFIB (oncogenic genes), and multiple NOTCH pathway genes including DLL3, as determined by ChIP-seq in SCLC.","method":"ChIP-seq, whole-genome microarray expression analysis, shRNA knockdown, CDK5 inhibition in vitro","journal":"Cell reports / PNAS","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP-seq and expression analysis with functional validation in multiple SCLC cell lines, two independent papers","pmids":["27452466","25267614"],"is_preprint":false},{"year":2015,"finding":"Ascl1 alone is sufficient to convert dorsal midbrain astrocytes into functional induced neurons in vivo; GFAP-AAV-mediated Ascl1 expression converts astrocytes in dorsal midbrain, striatum, and somatosensory cortex of postnatal and adult mice into neurons that form synaptic inputs and outputs with existing neurons.","method":"GFAP-AAV viral delivery in postnatal and adult mice, morphological analysis, electrophysiology, synaptic connectivity tracing","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo conversion with functional electrophysiological and synaptic connectivity validation","pmids":["26109658"],"is_preprint":false},{"year":2015,"finding":"Multi-site phosphorylation of Ascl1 at serine-proline motifs by CDKs inhibits its ability to induce differentiation of AVNA (anteroventral noradrenergic) cells; a phospho-mutant Ascl1 drives differentiation even when CDKs or MYCN are overexpressed, whereas wild-type Ascl1 is inhibited. This was shown in a Xenopus developmental model.","method":"Xenopus in vivo gain- and loss-of-function, phospho-mutant ASCL1 constructs, CDK overexpression, Xenopus AVNA cell differentiation assays","journal":"Disease models & mechanisms","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — phospho-site mutagenesis with in vivo functional readout, epistasis with CDKs/MYCN, single lab but multiple genetic manipulations","pmids":["25786414"],"is_preprint":false},{"year":2015,"finding":"The NOTCH-ASCL1-RB-p53 signaling axis drives secondary SCLC: NOTCH inactivating mutations lead to ASCL1 activation; ASCL1 inactivates RB via phosphorylation (reversible by CDK5 inhibition); this pathway was experimentally verified in vitro and validated by genetic alterations in vivo.","method":"In vitro cell line experiments with CDK5 inhibition, NGS of clinical samples, IHC, FISH; pathway epistasis analysis","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — functional in vitro validation of ASCL1-dependent RB phosphorylation plus CDK5 inhibitor reversal, single lab","pmids":["26340530"],"is_preprint":false},{"year":2015,"finding":"EZH2 promotes SCLC progression by epigenetically silencing TGF-β type II receptor (TβRII), thereby suppressing the TGF-β-Smad-ASCL1 pathway; ASCL1 is a Smad-dependent transcriptional target of TGF-β signaling that induces cell survival in SCLC.","method":"TβRII overexpression in SCLC cells, TGF-β treatment, EZH2 functional analysis, in vitro growth/apoptosis assays, in vivo tumor formation","journal":"Cell discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — functional experiments with defined pathway epistasis and in vivo validation, single lab","pmids":["27462425"],"is_preprint":false},{"year":2017,"finding":"ASCL1 functions as a pioneer factor in glioblastoma stem cells (GSCs), opening closed chromatin to activate a neurogenic gene expression program; ASCL1hi GSCs have latent capacity for terminal neuronal differentiation upon Notch inhibition, and increasing ASCL1 in ASCL1lo GSCs restores neuronal lineage potential, promotes differentiation, and attenuates tumorigenicity.","method":"ATAC-seq, ChIP-seq, Notch inhibition, ASCL1 overexpression in patient-derived GSCs, in vivo tumorigenicity assays, chromatin accessibility analysis","journal":"Cell stem cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — pioneer factor activity demonstrated by chromatin opening assays (ATAC-seq) combined with functional tumorigenicity and differentiation assays in patient-derived cells","pmids":["28712938"],"is_preprint":false},{"year":2018,"finding":"Subcellular localization modulates ASCL1 ubiquitylation and degradation: cytoplasmic ASCL1 harbors long ubiquitin chains and is targeted for proteasomal destruction via the E3 ligase Huwe1, with ubiquitin conjugated to lysines in the bHLH domain; chromatin-bound ASCL1 associates with short ubiquitin chains (on N-terminal or bHLH lysines, not mediated by Huwe1) and is not targeted for destruction.","method":"Subcellular fractionation, ubiquitylation assays, E3 ligase (Huwe1) knockdown/inhibition, site-directed mutagenesis of lysine residues","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — biochemical fractionation combined with mutagenesis, E3 ligase identification, and mechanistic dissection of two distinct ubiquitylation states","pmids":["29545540"],"is_preprint":false},{"year":2019,"finding":"Proneural factors Ascl1 and Neurog2 induce different neuronal fates by binding largely different genomic sites; their divergent binding patterns are not determined by prior chromatin state but are distinguished by enrichment of specific E-box sequences reflecting DNA-binding domain preferences. Divergent binding results in distinct chromatin accessibility and enhancer activity profiles that differentially shape binding of downstream transcription factors.","method":"Direct neuronal programming of ESCs, ChIP-seq, ATAC-seq, comparative genomic binding analysis, E-box motif analysis","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP-seq and ATAC-seq with mechanistic follow-up identifying E-box specificity as the determinant of divergent binding, multiple orthogonal methods","pmids":["31086315"],"is_preprint":false},{"year":2019,"finding":"High Hes1 expression in quiescent adult neural stem cells continuously suppresses Ascl1, keeping cells quiescent; oscillatory Hes1 drives cyclic Ascl1 expression in active neural stem cells, promoting proliferation. Inactivation of Hes1-related genes upregulates Ascl1 and increases neurogenesis, causing NSC depletion; sustained Hes1 represses Ascl1 and maintains quiescence. Induction of Ascl1 oscillations (rather than sustained expression) activates NSCs.","method":"Hes1 conditional knockout in adult mouse brain, live imaging of oscillatory expression, Hes1 sustained overexpression, neurogenesis quantification in vivo","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic manipulations in vivo combined with live imaging to dissect oscillatory vs. sustained expression states","pmids":["30862661"],"is_preprint":false},{"year":2019,"finding":"ASCL1 is a direct transcriptional target of LMO1 and MYCN in neuroblastoma; regulatory elements of ASCL1 are bound by LMO1, MYCN, and CRC transcription factors GATA3, HAND2, PHOX2B, TBX2, ISL1. ASCL1 is required for neuroblastoma cell growth and arrest of differentiation, and directly regulates expression of CRC genes.","method":"ChIP-seq, RNA-seq, ASCL1 knockdown functional assays in neuroblastoma cell lines","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP-seq demonstrating direct binding of multiple upstream regulators at ASCL1 locus, functional KD with defined proliferation and differentiation phenotypes","pmids":["31819055"],"is_preprint":false},{"year":2020,"finding":"Physical interaction between Gsx2 homeodomain protein and the bHLH domain of Ascl1 interferes with Ascl1 DNA binding, inhibiting neurogenesis in LGE ventricular zone progenitors; Ascl1-Gsx2 interactions are enriched in LGE VZ progenitors while Ascl1-E-protein (Tcf3) interactions predominate in the SVZ.","method":"Luciferase transcriptional assays, protein-protein interaction (Co-IP/proximity ligation assay in tissue sections), DNA-binding assays, Ascl1 misexpression in dorsal progenitors, Gsx2/Ascl1 co-expression experiments","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct protein interaction demonstrated by proximity ligation in tissue, DNA binding interference shown biochemically, functional transcriptional assays, in vivo validation","pmids":["32122989"],"is_preprint":false},{"year":2021,"finding":"Ascl1 directly regulates a set of target genes during astrocyte-to-neuron conversion including Klf10 (neuritogenesis), Myt1/Myt1l (electrophysiological maturation), and Neurod4/Chd7 (conversion efficiency); ChIP-seq identified 107 genes whose regulatory regions are directly bound by ASCL1 during early conversion.","method":"RNA-seq, ChIP-seq, siRNA knockdown of individual targets during astrocyte-to-neuron conversion, electrophysiology, morphological analysis","journal":"Stem cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP-seq combined with functional KD of individual direct targets with specific phenotypic readouts","pmids":["33577795"],"is_preprint":false},{"year":2021,"finding":"ASCL1 represses a SOX9+/RUNX1/RUNX2 neural crest stem-like program in MYC-driven SCLC; ASCL1 loss in MYC-driven SCLC promotes emergence of a SOX9+ mesenchymal state and osteosarcoma/chondroid tumors, while promoting neuroendocrine fate and NKX2-1/FOXA2/INSM1 expression; ASCL1 also represses Hippo/Wnt/Notch developmental pathway genes.","method":"Genetically engineered mouse models (GEMMs), genetic ASCL1 depletion, RNA-seq, in vivo tumor analysis, human SCLC cell SOX9 expression analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic depletion in multiple GEMMs with defined tumor identity phenotypes and transcriptomic analysis","pmids":["34016693"],"is_preprint":false},{"year":2021,"finding":"ASCL1 complexes with NKX2-1 and PROX1 to co-regulate genes functioning in NOTCH signaling, catecholamine biosynthesis, and cell-cycle processes in ASCL1-high SCLC; ASCL1 depletion reduces expression of multiple DepMap-defined essential genes.","method":"ChIP-seq, ATAC-seq, super-enhancer analysis, ASCL1 knockdown, Co-immunoprecipitation/interaction analysis of ASCL1/NKX2-1/PROX1","journal":"iScience","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP-seq demonstrating co-occupancy, protein complex identification, and KD functional analysis with defined gene expression targets","pmids":["34466783"],"is_preprint":false},{"year":2022,"finding":"ASCL1 acts as a pioneer factor to open closed chromatin and as a non-pioneer remodeler at permissive chromatin during human neural differentiation; ASCL1 interacts with BAF SWI/SNF chromatin remodeling complexes primarily at non-pioneer targets, with codependent DNA binding and remodeling at a subset of ASCL1/SWI/SNF co-targets.","method":"Single-cell transcriptomics, ASCL1 knockout model, ATAC-seq, ChIP-seq, Co-IP of ASCL1 with BAF complex subunits, chromatin conformation analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO defining unbound state, ATAC-seq showing chromatin opening, Co-IP identifying SWI/SNF interaction, multiple orthogonal methods in single rigorous study","pmids":["36931659"],"is_preprint":false},{"year":2022,"finding":"Ascl1 possesses cross-lineage reprogramming potential; together with Mef2c, it drives efficient cardiac reprogramming. MEF2C shifts ASCL1 binding away from neuronal genes toward cardiac genes, guiding cooperative epigenetic and transcriptional activity.","method":"ChIP-seq, RNA-seq, direct cardiac reprogramming assays, comparison of ASCL1 binding in neuronal vs. cardiac reprogramming contexts","journal":"Cell stem cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genome-wide ChIP-seq demonstrating MEF2C-dependent binding shift plus functional reprogramming assays, single lab with multiple orthogonal methods","pmids":["36206732"],"is_preprint":false},{"year":2022,"finding":"Elevated ASCL1 activity in neuroblastoma cells creates numerous additional low-affinity binding sites beyond endogenous sites; multi-site phosphorylation of ASCL1 limits this additional binding; preventing phosphorylation (phospho-mutant) further increases genome-wide binding and gene activation, redirecting the transcriptome from proliferative neuroblast state toward neuronal differentiation.","method":"ASCL1 overexpression and phospho-mutant expression in neuroblastoma cells, ChIP-seq, RNA-seq, genome-wide binding site analysis","journal":"BMC genomics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP-seq and RNA-seq comparing wild-type vs. phospho-mutant ASCL1 with functional transcriptomic readout, single lab multiple orthogonal methods","pmids":["35366798"],"is_preprint":false},{"year":2022,"finding":"ASCL1 acts as a driver of neuroendocrine lineage plasticity in prostate cancer via large-scale chromatin remodeling; ASCL1 motif is enriched in hyper-accessible chromatin regions after ARPI treatment; targeting ASCL1 switches neuroendocrine lineage back to luminal epithelial state via UHRF1/AMPK-mediated disruption of polycomb repressive complex-2.","method":"ATAC-seq, ChIP-seq, ASCL1 knockdown/overexpression, chromatin architecture analysis, UHRF1/AMPK pathway manipulation, in vivo tumor models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple chromatin assays, genetic manipulation of ASCL1 and downstream epigenetic machinery, in vivo validation","pmids":["35477723"],"is_preprint":false},{"year":2022,"finding":"ASCL1 phospho-mutant (Ascl1-SA6, six serine-to-alanine substitutions at SP motifs) is more effective than wild-type Ascl1 at converting adult cortical astrocytes to neurons in vivo; Ascl1-SA6 more efficiently represses astrocytic markers SOX9 and GFAP, promotes dendritic arbor maturation, and transduced astrocytes exhibit neuronal electrophysiological responses (faster decay of evoked potentials).","method":"AAV delivery in adult mouse cerebral cortex, Rosa reporter mice, immunofluorescence, patch-clamp electrophysiology, ChR2 optogenetic stimulation","journal":"Frontiers in neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Moderate — phospho-site mutagenesis combined with in vivo functional electrophysiological validation, multiple AAV/reporter combinations tested","pmids":["36061596"],"is_preprint":false},{"year":2022,"finding":"ASCL1 phosphorylation at SP sites and upregulation of ID2 are barriers to ASCL1-driven differentiation in GBM stem cells; a phospho-mutant ASCL1 (non-phosphorylatable at SP sites) drives GBM cells to neuronal lineage and out of cell cycle more efficiently; the effect is further enhanced by deletion of ID2.","method":"Phospho-mutant ASCL1 overexpression in GBM stem cells, CRISPR-mediated ID2 deletion, cell cycle analysis, neuronal differentiation assays","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — phospho-site mutagenesis combined with genetic deletion of inhibitor, functional differentiation and cell cycle readouts, single lab multiple methods","pmids":["35149717"],"is_preprint":false},{"year":2023,"finding":"Ascl1 rapidly dismantles the pluripotency network during ESC-to-neuron conversion, while Ngn2 generates a neural stem cell-like intermediate via incomplete pluripotency network shutdown; Ascl1 relies more on Tcf7l1 for cell cycle exit (in Tcf7l1 KO, Ascl1 represses pluripotency genes but fails to exit cell cycle; overexpression of Cdkn1c restores cell cycle exit and neuronal generation).","method":"CRISPR-Cas9 KO screening, RNA-seq, ChIP-seq, direct ESC-to-neuron conversion, Cdkn1c overexpression rescue experiments","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide CRISPR screen with mechanistic follow-up via KO/rescue experiments and transcriptomic analysis","pmids":["37660160"],"is_preprint":false},{"year":2014,"finding":"EWS-WT1 oncoprotein directly activates ASCL1 transcription by binding the proximal ASCL1 promoter through multiple WT1-responsive elements; EWS-WT1 silencing in DSRCT cells reduces ASCL1 expression and cell viability.","method":"ChIP assay, luciferase reporter assays with ASCL1 promoter, EWS-WT1 knockdown/transgenic mouse, DSRCT cell functional assays","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and promoter reporter assays with functional KD validation, single lab","pmids":["24934812"],"is_preprint":false},{"year":2011,"finding":"Gli2 directly binds multiple regulatory regions (promoter and enhancer) of the Ascl1 gene and activates its promoter in vitro; Gli2 upregulates Ascl1 to induce neurogenesis, and dominant-negative Gli2 significantly downregulates Ascl1 expression, causing delayed neurogenesis.","method":"ChIP assays, luciferase reporter assays with Ascl1 promoter, Gli2 overexpression and dominant-negative Gli2 in P19 cells","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter assay with dominant-negative functional validation, single lab in cell line model","pmids":["21559470"],"is_preprint":false},{"year":2010,"finding":"ASCL1 regulates expression of the CHRNA5/A3/B4 nicotinic acetylcholine receptor gene cluster in SCLC; knockdown of ASCL1 specifically decreases alpha3 and beta4 subunit expression without affecting other nAChR genes, indicating a specific regulatory relationship.","method":"ASCL1 shRNA knockdown in SCLC and non-SCLC cells, qRT-PCR, in silico promoter analysis identifying ASCL1 binding sites","journal":"Molecular cancer research : MCR","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — KD with specific gene expression readout, replicated in multiple cell lines, no direct binding demonstrated","pmids":["20124469"],"is_preprint":false},{"year":2019,"finding":"ASCL1 regulates Wnt11 expression via H3K27 acetylation at the WNT11 gene enhancer region; ASCL1 knockdown downregulates Wnt11 in SCLC; Wnt11 in turn controls neuroendocrine differentiation, cell proliferation, and E-cadherin expression downstream of ASCL1, with AKT and p38 MAPK phosphorylation increased by Wnt11.","method":"ASCL1 transfection into A549 cells, ASCL1 knockdown in SCLC lines, ChIP for H3K27ac at WNT11 enhancer, WNT11 knockdown functional assays","journal":"Laboratory investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP showing epigenetic regulation combined with KD functional assays, single lab","pmids":["31231131"],"is_preprint":false},{"year":2011,"finding":"Phorbol ester (PMA) suppresses hASH1 (ASCL1) synthesis via distinct sequential mechanisms: short-term inhibition through mRNA destabilization dependent mainly on protein kinase C activity; prolonged suppression (48h) through decreased ASCL1 promoter activity and inhibition of mRNA translation.","method":"Reporter gene assays (promoter-luciferase and UTR-luciferase), PKC inhibitor experiments, mRNA stability assays in neuroblastoma-derived Kelly cells","journal":"Frontiers in molecular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assays with UTR and promoter constructs combined with PKC inhibitor pharmacology, single lab","pmids":["21441980"],"is_preprint":false},{"year":2015,"finding":"Maternal Ascl1 protein in Xenopus represses VegT-induced mesendoderm (but not Nodal-induced mesendoderm); a previously uncharacterized N-terminal domain of Ascl1 interacts with HDAC1 to inhibit mesendoderm gene expression via histone deacetylation at VegT target promoters; this N-terminal domain is dispensable for neurogenic function, indicating distinct mechanisms for different functions.","method":"Gain- and loss-of-function experiments in Xenopus, domain deletion mutants, HDAC interaction assay, HDAC inhibitor treatment, ChIP for histone acetylation at target gene promoters","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — domain mutagenesis, HDAC interaction demonstration, ChIP for histone marks, functional in vivo assays showing domain-specific mechanism","pmids":["26700681"],"is_preprint":false},{"year":2023,"finding":"ROR2 receptor tyrosine kinase activates the ERK/CREB signaling pathway to modulate ASCL1 expression in prostate cancer; ROR2 upregulation following AR pathway inhibition feeds into lineage plasticity via ASCL1 activation.","method":"RTK screen, ROR2 knockdown/overexpression, ERK/CREB pathway inhibitor experiments, ASCL1 expression analysis in prostate cancer cells","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — RTK screen with functional validation via pathway inhibitors, single lab but multiple approaches to link ROR2/CREB to ASCL1","pmids":["37552603"],"is_preprint":false},{"year":2024,"finding":"ASCL1 is required for neuroendocrine differentiation in prostate cancer in vivo; genetic loss of Ascl1 in RPM (Rb1-/-/Trp53-/-/Myc+) mouse prostate organoid allografts decreases NE identity and increases basal-like identity without affecting tumor incidence, growth, or metastasis.","method":"Genetically engineered mouse prostate organoids with Cre-induced Rb1/Trp53 loss and Myc overexpression, Ascl1 conditional genetic deletion, histopathology, immunofluorescence, scRNA-seq","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — conditional genetic KO in in vivo allograft model with defined lineage identity phenotype and transcriptomic analysis","pmids":["39264686"],"is_preprint":false},{"year":2024,"finding":"ASCL1+ cells arise from KRT8+ luminal cells during neuroendocrine prostate cancer (NEPC) transition; Ascl1 loss before transplantation abrogates lineage plasticity, resulting in castration-sensitive adenocarcinomas, while Ascl1 deletion in established NEPC causes only transient regression.","method":"Multiplexed immunofluorescence, spatial transcriptomics, Ascl1 conditional deletion at different stages, in vivo mouse prostate organoid transplantation model","journal":"Nature cancer","confidence":"High","confidence_rationale":"Tier 2 / Strong — spatial transcriptomics and multiplexed IF for lineage tracing combined with stage-specific Ascl1 deletion revealing distinct functional requirements","pmids":["39394434"],"is_preprint":false},{"year":2024,"finding":"SMAD4 competes with Myc to regulate ASCL1 transcription in NSCLC cells; SMAD4 deficiency accelerates SCLC transition by inducing neuroendocrine phenotype through increased ASCL1 transcription, independently of RB1 status in TP53-deficient cells.","method":"CRISPR-Cas9 SMAD4/RB1 knockout in HCC827 and A549-TP53-/- cells, Myc inhibitor treatment, in vitro and in vivo tumor models, mRNA and protein expression analysis","journal":"Cell communication and signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR KO with functional in vivo readout and Myc competition mechanism, single lab","pmids":["38233864"],"is_preprint":false},{"year":2024,"finding":"ASCL1 confers drug tolerance to osimertinib in EGFR mutant lung cancer by initiating an epithelial-to-mesenchymal gene-expression program in permissive cellular contexts; this effect is context-specific and not observed in all tumor types.","method":"Patient-derived xenograft models, single-cell transcriptional profiling, osimertinib treatment to maximal regression, ASCL1 expression analysis in residual disease","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — scRNA-seq in PDX models identifying mechanistic transcriptional program, but ASCL1's causal role in EMT inferred rather than demonstrated by direct manipulation","pmids":["38359163"],"is_preprint":false}],"current_model":"ASCL1 is a bHLH pioneer transcription factor that binds E-box sequences in open and closed chromatin (the latter via pioneer activity), interacts with the BAF SWI/SNF complex and with protein partners (Neurog2, Gsx2, NKX2-1, PROX1, HDAC1) to open chromatin and activate neurogenic/neuroendocrine gene programs; its activity is restrained by multi-site CDK-mediated serine-proline phosphorylation, which limits DNA binding and differentiation-promoting activity, while subcellular localization determines its ubiquitylation by Huwe1 and proteasomal degradation; upstream, its expression is oscillatorily controlled by Hes1 (which suppresses it to maintain quiescence), and it is directly activated by Gli2, LMO1/MYCN, EWS-WT1, and ROR2/CREB signaling, positioning ASCL1 as a context-dependent master regulator of neurogenesis, gliogenesis, and neuroendocrine lineage commitment in both normal development and cancer."},"narrative":{"mechanistic_narrative":"ASCL1 is a basic helix-loop-helix (bHLH) proneural transcription factor that acts as a context-dependent master regulator of neuronal, glial, and neuroendocrine lineage commitment in development and cancer [PMID:15133515, PMID:28712938]. It binds E-box sequences as homodimers or as heterodimers with Neurog2, and functions as a pioneer factor capable of opening closed chromatin to activate neurogenic gene programs; at permissive sites it acts as a non-pioneer remodeler, interacting with BAF SWI/SNF complexes for co-dependent DNA binding and remodeling [PMID:19389376, PMID:28712938, PMID:36931659]. During neurogenesis ASCL1 specifies diverse fates—serotonergic neurons via Gata3/Lmx1b/Pet1, GABAergic interneurons, and oligodendrocytes in collaboration with Olig2 and Nkx2-2—and the choice between excitatory and inhibitory output is shaped by partners and downstream targets including Tlx3, Ptf1a, and Notch [PMID:16715081, PMID:15133515, PMID:18287202, PMID:21795554]. ASCL1 alone is sufficient to reprogram fibroblasts, ESCs, and astrocytes into functional neurons, dismantling the pluripotency network and driving cell-cycle exit through Tcf7l1/Cdkn1c, while co-expression with MEF2C redirects it toward cardiac fates [PMID:25254342, PMID:26109658, PMID:36206732, PMID:37660160]. Its activity is constrained at several levels: multi-site CDK-mediated serine-proline phosphorylation limits genome-wide DNA binding and differentiation-promoting activity, subcellular localization governs Huwe1-mediated ubiquitylation and proteasomal degradation, and protein partners such as Gsx2 and the inhibitor ID2 antagonize its function [PMID:25786414, PMID:29545540, PMID:33577795, PMID:35149717]. Upstream, ASCL1 expression is held in check by Hes1, whose sustained versus oscillatory expression gates neural stem cell quiescence versus activation [PMID:30862661]. In cancer, ASCL1 drives neuroendocrine identity in small-cell lung cancer—complexing with NKX2-1 and PROX1 and activating NOTCH, RB1, and catecholamine biosynthesis targets—and mediates neuroendocrine lineage plasticity in prostate cancer through large-scale chromatin remodeling [PMID:27452466, PMID:25267614, PMID:34016693, PMID:34466783, PMID:35477723, PMID:39394434]. A separable N-terminal domain recruits HDAC1 to repress mesendoderm genes, illustrating that ASCL1 deploys distinct activating and repressive mechanisms for different programs [PMID:26700681].","teleology":[{"year":2004,"claim":"Establishing that ASCL1 is not merely a generic proneural factor but a determinant of specific neurotransmitter identity answered how a single bHLH factor links cell-cycle exit to phenotype specification.","evidence":"Mouse Ascl1 knockout with analysis of serotonergic marker activation in vivo","pmids":["15133515"],"confidence":"High","gaps":["Direct binding of ASCL1 to Gata3/Lmx1b/Pet1 loci not shown","Mechanism distinguishing proneural from phenotype-specifying functions undefined"]},{"year":2006,"claim":"Defining how ASCL1 coordinately controls fate choices clarified that it can both promote inhibitory differentiation and, via Notch, ensure excitatory neuron generation, revealing combinatorial and feedback logic.","evidence":"Mouse knockout and genetic epistasis with Tlx3/Gsh and Ptf1a in spinal cord, plus inducible fate mapping","pmids":["16715081","17166924"],"confidence":"High","gaps":["Direct vs. indirect regulation of Ptf1a/Tlx3 not fully resolved","Temporal switch from neuronal to oligodendrocyte progenitor identity mechanistically unexplained"]},{"year":2008,"claim":"Showing ASCL1 cooperates combinatorially with Olig2 and Nkx2-2 extended its role beyond neurons into oligodendrocyte differentiation and gliogenesis.","evidence":"Ascl1 knockout plus gain-of-function combinatorial overexpression in OLP cultures","pmids":["18287202"],"confidence":"High","gaps":["Physical interaction of ASCL1 with Olig2/Nkx2-2 not demonstrated","Shared vs. distinct genomic targets unmapped"]},{"year":2009,"claim":"Direct ChIP and E-box mutagenesis at the Dll3 promoter established ASCL1 as a sequence-specific DNA binder acting through homodimers and Neurog2 heterodimers, with E-boxes conferring either activation or repression.","evidence":"Transgenic reporter mice, E-box mutagenesis, ChIP, and in vitro DNA binding","pmids":["19389376"],"confidence":"High","gaps":["Identity of additional factors required for efficient binding unknown","Structural basis of enhancer vs. repressor E-box discrimination undefined"]},{"year":2013,"claim":"Identifying FOXO3 as a co-binding factor that restrains ASCL1-dependent neurogenesis and the Hes1-ASCL1 relationship began mapping the upstream regulatory architecture governing ASCL1 output.","evidence":"ChIP-seq for FOXO3 and ASCL1 with loss-of-function neurogenesis assays in NPCs and fibroblasts","pmids":["23891001"],"confidence":"High","gaps":["Whether FOXO3 acts by direct competition or recruitment unresolved","Brain oligodendrogenesis role (PMID 23739972) mechanistically separate from binding studies"]},{"year":2014,"claim":"Demonstrating that ASCL1 alone suffices to generate functional neurons from fibroblasts and ESCs established it as a deterministic reprogramming factor and a tool for lineage conversion.","evidence":"Single-factor forced expression with electrophysiology and synaptic characterization","pmids":["25254342"],"confidence":"High","gaps":["Why single-factor neurons default to excitatory identity not explained","Chromatin requirements for reprogramming competence not addressed here"]},{"year":2014,"claim":"Connecting ASCL1 to cancer, work showed it directly activates RB1 in a phosphorylation-dependent manner and drives oncogenic and NOTCH target programs in SCLC, plus upstream activation by EWS-WT1.","evidence":"ChIP-seq, expression profiling, shRNA, CDK5 inhibition in SCLC; ChIP and reporter assays for EWS-WT1","pmids":["27452466","25267614","24934812"],"confidence":"High","gaps":["EWS-WT1 link is Medium-confidence single lab","Causal hierarchy among ASCL1 oncogenic targets not dissected"]},{"year":2015,"claim":"Defining multi-site CDK phosphorylation as an inhibitory switch answered how ASCL1's differentiation-promoting activity is held in check despite its presence in cycling progenitors.","evidence":"Xenopus phospho-mutant constructs with CDK/MYCN epistasis and AVNA differentiation assays","pmids":["25786414"],"confidence":"High","gaps":["Identity of the specific CDKs acting in each context not fully resolved","Phosphatases reversing the modification unknown"]},{"year":2015,"claim":"Pathway-level studies placed ASCL1 within a NOTCH-ASCL1-RB-p53 axis and a TGF-β-Smad-ASCL1 survival pathway, situating it in cancer signaling networks.","evidence":"In vitro CDK5 inhibition, clinical NGS/IHC, and TβRII/EZH2/TGF-β manipulation in SCLC","pmids":["26340530","27462425"],"confidence":"Medium","gaps":["Both are single-lab Medium-confidence","Direct vs. indirect Smad regulation of the ASCL1 locus not established"]},{"year":2017,"claim":"Direct demonstration of pioneer activity in glioblastoma stem cells showed ASCL1 opens closed chromatin to license a latent neuronal differentiation program suppressed by Notch.","evidence":"ATAC-seq, ChIP-seq, Notch inhibition, and ASCL1 overexpression in patient-derived GSCs with in vivo tumorigenicity","pmids":["28712938"],"confidence":"High","gaps":["Molecular determinants of pioneer-competent sites not defined here","Co-factors enabling chromatin opening unidentified"]},{"year":2018,"claim":"Linking subcellular localization to ubiquitylation state identified Huwe1-mediated cytoplasmic degradation versus a stable chromatin-bound pool, adding post-translational control of ASCL1 abundance.","evidence":"Subcellular fractionation, ubiquitylation assays, Huwe1 knockdown, and lysine mutagenesis","pmids":["29545540"],"confidence":"High","gaps":["Signals directing cytoplasmic vs. nuclear partitioning unknown","Function of short chromatin-associated ubiquitin chains undefined"]},{"year":2019,"claim":"Comparative genomics resolved why ASCL1 and Neurog2 induce distinct fates—divergent binding driven by intrinsic E-box preference rather than prior chromatin state—clarifying the basis of bHLH binding specificity.","evidence":"Direct ESC programming with ChIP-seq, ATAC-seq, and E-box motif analysis","pmids":["31086315"],"confidence":"High","gaps":["DNA-binding domain residues conferring preference not mapped","Role of downstream factors in reinforcing divergence partially defined"]},{"year":2019,"claim":"Demonstrating that oscillatory versus sustained Hes1 gates ASCL1 dynamics established the upstream timer controlling neural stem cell quiescence versus activation, and identified LMO1/MYCN as direct activators of ASCL1 in neuroblastoma.","evidence":"Hes1 conditional KO with live imaging in adult brain; ChIP-seq/RNA-seq with ASCL1 knockdown in neuroblastoma","pmids":["30862661","31819055"],"confidence":"High","gaps":["How ASCL1 protein level decodes oscillatory input mechanistically unresolved","WNT11/CHRNA target regulation (Medium-confidence) less directly validated"]},{"year":2020,"claim":"Identifying a direct Gsx2-bHLH interaction that blocks ASCL1 DNA binding revealed a partner-switch mechanism (Gsx2 in VZ vs. E-protein in SVZ) that spatially tunes neurogenic output.","evidence":"Proximity ligation in tissue, Co-IP, DNA-binding interference assays, and in vivo misexpression","pmids":["32122989"],"confidence":"High","gaps":["Structural basis of Gsx2-bHLH contact not determined","Whether other homeodomain factors act similarly unknown"]},{"year":2021,"claim":"GEMM and complex studies defined ASCL1's repressive role restraining a SOX9 mesenchymal program and its complexing with NKX2-1/PROX1 to maintain neuroendocrine SCLC identity.","evidence":"Genetic ASCL1 depletion in GEMMs with RNA-seq; ChIP-seq, ATAC-seq, and Co-IP of ASCL1/NKX2-1/PROX1","pmids":["34016693","34466783"],"confidence":"High","gaps":["Mechanism of ASCL1-mediated repression of Hippo/Wnt/Notch genes unresolved","Stoichiometry and architecture of the ASCL1/NKX2-1/PROX1 complex undefined"]},{"year":2022,"claim":"Mechanistic dissection separated ASCL1's pioneer and non-pioneer modes and identified BAF SWI/SNF as a partner at non-pioneer targets, and showed phosphorylation and ID2 act as differentiation barriers in neuroblastoma and GBM.","evidence":"scRNA-seq, ATAC-seq, ChIP-seq, ASCL1 KO and Co-IP with BAF subunits; phospho-mutant and ID2-deletion functional assays in NB/GBM","pmids":["36931659","35366798","35149717","36061596"],"confidence":"High","gaps":["Determinants selecting pioneer vs. non-pioneer engagement incompletely defined","How phosphorylation restricts low-affinity site occupancy mechanistically unresolved"]},{"year":2022,"claim":"Cross-lineage and cancer-plasticity studies showed MEF2C redirects ASCL1 to cardiac genes and that ASCL1 drives neuroendocrine prostate plasticity via UHRF1/AMPK-mediated PRC2 disruption.","evidence":"ChIP-seq/RNA-seq cardiac reprogramming; ATAC-seq/ChIP-seq with UHRF1/AMPK manipulation and in vivo prostate tumor models","pmids":["36206732","35477723"],"confidence":"High","gaps":["How MEF2C physically retargets ASCL1 binding undefined","Direct vs. indirect connection between ASCL1 and PRC2 disruption not fully resolved"]},{"year":2023,"claim":"Defining the divergent reprogramming logic of ASCL1 (rapid pluripotency dismantling, Tcf7l1/Cdkn1c-dependent cell-cycle exit) clarified the molecular steps by which it overrides existing cell identity, and identified ROR2/ERK/CREB as an upstream activator in prostate cancer.","evidence":"CRISPR KO screen with RNA-seq/ChIP-seq and Cdkn1c rescue; RTK screen with pathway inhibitors in prostate cancer","pmids":["37660160","37552603"],"confidence":"High","gaps":["Whether Tcf7l1 dependency is direct or via downstream effectors not fully resolved","ROR2/CREB-to-ASCL1 link is Medium-confidence single lab"]},{"year":2024,"claim":"Stage-specific genetic studies established ASCL1 as required for initiating but not always maintaining neuroendocrine prostate plasticity, defined SMAD4-Myc competition over ASCL1 transcription, and linked ASCL1 to drug tolerance via an EMT program.","evidence":"Conditional Ascl1 deletion at different stages in prostate organoid allografts with scRNA-seq/spatial transcriptomics; CRISPR SMAD4/RB1 KO; PDX scRNA-seq under osimertinib","pmids":["39264686","39394434","38233864","38359163"],"confidence":"High","gaps":["Why established NEPC becomes ASCL1-independent unexplained","EMT/drug-tolerance role (Medium-confidence) inferred rather than directly manipulated"]},{"year":null,"claim":"How ASCL1 integrates phosphorylation state, partner availability, and chromatin context to switch between pioneering, non-pioneering, activating, and repressive modes at the level of structure and recruitment remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No structural model of ASCL1 on pioneer-competent nucleosomal DNA","Rules dictating activator vs. repressor output at individual E-boxes undefined","Phosphatases and full kinase repertoire controlling the phospho-switch unidentified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,4,9,14,18]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[4,16,20]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[14,23]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[15,23]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[15]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[4,14,23]}],"pathway":[{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,1,3,5,8]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[4,9,18,22]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[14,23,26]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[9,21,22,26,38]}],"complexes":["BAF (SWI/SNF) complex","ASCL1/NKX2-1/PROX1 complex"],"partners":["NEUROG2","GSX2","NKX2-1","PROX1","HDAC1","MEF2C","OLIG2","ID2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P50553","full_name":"Achaete-scute homolog 1","aliases":["Class A basic helix-loop-helix protein 46","bHLHa46"],"length_aa":236,"mass_kda":25.5,"function":"Transcription factor that plays a key role in neuronal differentiation: acts as a pioneer transcription factor, accessing closed chromatin to allow other factors to bind and activate neural pathways. Directly binds the E box motif (5'-CANNTG-3') on promoters and promotes transcription of neuronal genes. The combination of three transcription factors, ASCL1, POU3F2/BRN2 and MYT1L, is sufficient to reprogram fibroblasts and other somatic cells into induced neuronal (iN) cells in vitro. Plays a role at early stages of development of specific neural lineages in most regions of the CNS, and of several lineages in the PNS. Essential for the generation of olfactory and autonomic neurons. Acts synergistically with FOXN4 to specify the identity of V2b neurons rather than V2a from bipotential p2 progenitors during spinal cord neurogenesis, probably through DLL4-NOTCH signaling activation. Involved in the regulation of neuroendocrine cell development in the glandular stomach (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P50553/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ASCL1","classification":"Not Classified","n_dependent_lines":30,"n_total_lines":1208,"dependency_fraction":0.024834437086092714},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ASCL1","total_profiled":1310},"omim":[{"mim_id":"621003","title":"TRANSCRIPTION FACTOR Sp9; SP9","url":"https://www.omim.org/entry/621003"},{"mim_id":"618646","title":"DIENCEPHALIC-MESENCEPHALIC JUNCTION DYSPLASIA SYNDROME 2; DMJDS2","url":"https://www.omim.org/entry/618646"},{"mim_id":"617578","title":"FER3-LIKE bHLH TRANSCRIPTION FACTOR; FERD3L","url":"https://www.omim.org/entry/617578"},{"mim_id":"617546","title":"HELT bHLH TRANSCRIPTION FACTOR; HELT","url":"https://www.omim.org/entry/617546"},{"mim_id":"616741","title":"PR DOMAIN-CONTAINING PROTEIN 13; PRDM13","url":"https://www.omim.org/entry/616741"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"brain","ntpm":15.5},{"tissue":"liver","ntpm":10.4},{"tissue":"pituitary gland","ntpm":28.2}],"url":"https://www.proteinatlas.org/search/ASCL1"},"hgnc":{"alias_symbol":["ASH1","HASH1","bHLHa46"],"prev_symbol":[]},"alphafold":{"accession":"P50553","domains":[{"cath_id":"4.10.280.10","chopping":"118-188","consensus_level":"medium","plddt":94.6341,"start":118,"end":188}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P50553","model_url":"https://alphafold.ebi.ac.uk/files/AF-P50553-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P50553-F1-predicted_aligned_error_v6.png","plddt_mean":67.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ASCL1","jax_strain_url":"https://www.jax.org/strain/search?query=ASCL1"},"sequence":{"accession":"P50553","fasta_url":"https://rest.uniprot.org/uniprotkb/P50553.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P50553/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P50553"}},"corpus_meta":[{"pmid":"33011388","id":"PMC_33011388","title":"SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization.","date":"2020","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33011388","citation_count":431,"is_preprint":false},{"pmid":"27452466","id":"PMC_27452466","title":"ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27452466","citation_count":419,"is_preprint":false},{"pmid":"25254342","id":"PMC_25254342","title":"Generation of induced neuronal cells by the single reprogramming factor ASCL1.","date":"2014","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/25254342","citation_count":300,"is_preprint":false},{"pmid":"25267614","id":"PMC_25267614","title":"ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25267614","citation_count":230,"is_preprint":false},{"pmid":"26109658","id":"PMC_26109658","title":"Ascl1 Converts Dorsal Midbrain Astrocytes into Functional Neurons In Vivo.","date":"2015","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26109658","citation_count":203,"is_preprint":false},{"pmid":"26340530","id":"PMC_26340530","title":"NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.","date":"2015","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26340530","citation_count":158,"is_preprint":false},{"pmid":"16715081","id":"PMC_16715081","title":"Ascl1 and Gsh1/2 control inhibitory and excitatory cell fate in spinal sensory interneurons.","date":"2006","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16715081","citation_count":155,"is_preprint":false},{"pmid":"15133515","id":"PMC_15133515","title":"Ascl1/Mash1 is required for the development of central serotonergic neurons.","date":"2004","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/15133515","citation_count":154,"is_preprint":false},{"pmid":"28712938","id":"PMC_28712938","title":"ASCL1 Reorganizes Chromatin to Direct Neuronal Fate and Suppress Tumorigenicity of Glioblastoma Stem Cells.","date":"2017","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/28712938","citation_count":144,"is_preprint":false},{"pmid":"17166924","id":"PMC_17166924","title":"Ascl1 defines sequentially generated lineage-restricted neuronal and oligodendrocyte precursor cells in the spinal cord.","date":"2006","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/17166924","citation_count":140,"is_preprint":false},{"pmid":"30862661","id":"PMC_30862661","title":"High Hes1 expression and resultant Ascl1 suppression regulate quiescent vs. active neural stem cells in the adult mouse brain.","date":"2019","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/30862661","citation_count":132,"is_preprint":false},{"pmid":"23891001","id":"PMC_23891001","title":"FOXO3 shares common targets with ASCL1 genome-wide and inhibits ASCL1-dependent neurogenesis.","date":"2013","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/23891001","citation_count":128,"is_preprint":false},{"pmid":"35477723","id":"PMC_35477723","title":"ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35477723","citation_count":122,"is_preprint":false},{"pmid":"21795554","id":"PMC_21795554","title":"Ascl1 genetics reveals insights into cerebellum local circuit assembly.","date":"2011","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/21795554","citation_count":119,"is_preprint":false},{"pmid":"18585058","id":"PMC_18585058","title":"Ascl1 (Mash1) lineage cells contribute to discrete cell populations in CNS architecture.","date":"2008","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/18585058","citation_count":118,"is_preprint":false},{"pmid":"23739972","id":"PMC_23739972","title":"Ascl1/Mash1 promotes brain oligodendrogenesis during myelination and remyelination.","date":"2013","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23739972","citation_count":117,"is_preprint":false},{"pmid":"21771810","id":"PMC_21771810","title":"Ascl1 expression defines a subpopulation of lineage-restricted progenitors in the mammalian retina.","date":"2011","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21771810","citation_count":106,"is_preprint":false},{"pmid":"31086315","id":"PMC_31086315","title":"Proneural factors Ascl1 and Neurog2 contribute to neuronal subtype identities by establishing distinct chromatin landscapes.","date":"2019","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31086315","citation_count":100,"is_preprint":false},{"pmid":"16103883","id":"PMC_16103883","title":"Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16103883","citation_count":99,"is_preprint":false},{"pmid":"27462425","id":"PMC_27462425","title":"EZH2 promotes progression of small cell lung cancer by suppressing the TGF-β-Smad-ASCL1 pathway.","date":"2015","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/27462425","citation_count":99,"is_preprint":false},{"pmid":"19389376","id":"PMC_19389376","title":"Ascl1 and Neurog2 form novel complexes and regulate Delta-like3 (Dll3) expression in the neural tube.","date":"2009","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/19389376","citation_count":91,"is_preprint":false},{"pmid":"18287202","id":"PMC_18287202","title":"Ascl1 is required for oligodendrocyte development in the spinal cord.","date":"2008","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/18287202","citation_count":82,"is_preprint":false},{"pmid":"14657947","id":"PMC_14657947","title":"hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors.","date":"2004","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/14657947","citation_count":81,"is_preprint":false},{"pmid":"31819055","id":"PMC_31819055","title":"ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31819055","citation_count":73,"is_preprint":false},{"pmid":"25520623","id":"PMC_25520623","title":"Transcriptional control of vertebrate neurogenesis by the proneural factor Ascl1.","date":"2014","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25520623","citation_count":67,"is_preprint":false},{"pmid":"34016693","id":"PMC_34016693","title":"ASCL1 represses a SOX9+ neural crest stem-like state in small cell lung cancer.","date":"2021","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/34016693","citation_count":65,"is_preprint":false},{"pmid":"17146289","id":"PMC_17146289","title":"Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2.","date":"2006","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/17146289","citation_count":59,"is_preprint":false},{"pmid":"39394434","id":"PMC_39394434","title":"The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1.","date":"2024","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39394434","citation_count":54,"is_preprint":false},{"pmid":"26732729","id":"PMC_26732729","title":"miR-124-9-9* potentiates Ascl1-induced reprogramming of cultured Müller glia.","date":"2016","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/26732729","citation_count":54,"is_preprint":false},{"pmid":"34466783","id":"PMC_34466783","title":"ASCL1, NKX2-1, and PROX1 co-regulate subtype-specific genes in small-cell lung cancer.","date":"2021","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/34466783","citation_count":49,"is_preprint":false},{"pmid":"31068386","id":"PMC_31068386","title":"Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).","date":"2019","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/31068386","citation_count":49,"is_preprint":false},{"pmid":"30538287","id":"PMC_30538287","title":"The proneural gene ASCL1 governs the transcriptional subgroup affiliation in glioblastoma stem cells by directly repressing the mesenchymal gene NDRG1.","date":"2018","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/30538287","citation_count":48,"is_preprint":false},{"pmid":"15013216","id":"PMC_15013216","title":"The Notch signaling cascade in neuroblastoma: role of the basic helix-loop-helix proteins HASH-1 and HES-1.","date":"2004","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/15013216","citation_count":46,"is_preprint":false},{"pmid":"25249462","id":"PMC_25249462","title":"Ascl1 controls the number and distribution of astrocytes and oligodendrocytes in the gray matter and white matter of the spinal cord.","date":"2014","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25249462","citation_count":44,"is_preprint":false},{"pmid":"36931659","id":"PMC_36931659","title":"Pioneer factor ASCL1 cooperates with the mSWI/SNF complex at distal regulatory elements to regulate human neural differentiation.","date":"2023","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/36931659","citation_count":43,"is_preprint":false},{"pmid":"24037524","id":"PMC_24037524","title":"ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiation.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24037524","citation_count":43,"is_preprint":false},{"pmid":"28181538","id":"PMC_28181538","title":"Epigenetic Editing of Ascl1 Gene in Neural Stem Cells by Optogenetics.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28181538","citation_count":43,"is_preprint":false},{"pmid":"21559470","id":"PMC_21559470","title":"Ascl1/Mash1 is a novel target of Gli2 during Gli2-induced neurogenesis in P19 EC cells.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21559470","citation_count":43,"is_preprint":false},{"pmid":"33577795","id":"PMC_33577795","title":"Molecular Mechanisms Underlying Ascl1-Mediated Astrocyte-to-Neuron Conversion.","date":"2021","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33577795","citation_count":41,"is_preprint":false},{"pmid":"11948117","id":"PMC_11948117","title":"Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features.","date":"2002","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/11948117","citation_count":40,"is_preprint":false},{"pmid":"23616538","id":"PMC_23616538","title":"Genome-wide expression analysis of Ptf1a- and Ascl1-deficient mice reveals new markers for distinct dorsal horn interneuron populations contributing to nociceptive reflex plasticity.","date":"2013","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23616538","citation_count":40,"is_preprint":false},{"pmid":"23284756","id":"PMC_23284756","title":"Ascl1 (Mash1) knockout perturbs differentiation of nonneuronal cells in olfactory epithelium.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23284756","citation_count":40,"is_preprint":false},{"pmid":"27076429","id":"PMC_27076429","title":"Ascl1 Is Required for the Development of Specific Neuronal Subtypes in the Enteric Nervous System.","date":"2016","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27076429","citation_count":38,"is_preprint":false},{"pmid":"35263037","id":"PMC_35263037","title":"Promoters of ASCL1- and NEUROD1-dependent genes are specific targets of lurbinectedin in SCLC cells.","date":"2022","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35263037","citation_count":37,"is_preprint":false},{"pmid":"32573857","id":"PMC_32573857","title":"ASCL1 regulates neurodevelopmental transcription factors and cell cycle genes in brain tumors of glioma mouse models.","date":"2020","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/32573857","citation_count":37,"is_preprint":false},{"pmid":"32788677","id":"PMC_32788677","title":"Developmental changes in the accessible chromatin, transcriptome and Ascl1-binding correlate with the loss in Müller Glial regenerative potential.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32788677","citation_count":36,"is_preprint":false},{"pmid":"24934812","id":"PMC_24934812","title":"EWS-WT1 oncoprotein activates neuronal reprogramming factor ASCL1 and promotes neural differentiation.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24934812","citation_count":35,"is_preprint":false},{"pmid":"31231131","id":"PMC_31231131","title":"Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.","date":"2019","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31231131","citation_count":35,"is_preprint":false},{"pmid":"25786414","id":"PMC_25786414","title":"Ascl1 phospho-status regulates neuronal differentiation in a Xenopus developmental model of neuroblastoma.","date":"2015","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/25786414","citation_count":35,"is_preprint":false},{"pmid":"30771509","id":"PMC_30771509","title":"Ascl1 Regulates Electric Field-Induced Neuronal Differentiation Through PI3K/Akt Pathway.","date":"2019","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30771509","citation_count":34,"is_preprint":false},{"pmid":"32065989","id":"PMC_32065989","title":"ASCL1- and DLX2-induced GABAergic neurons from hiPSC-derived NPCs.","date":"2020","source":"Journal of neuroscience methods","url":"https://pubmed.ncbi.nlm.nih.gov/32065989","citation_count":34,"is_preprint":false},{"pmid":"36206732","id":"PMC_36206732","title":"Cross-lineage potential of Ascl1 uncovered by comparing diverse reprogramming regulatomes.","date":"2022","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/36206732","citation_count":34,"is_preprint":false},{"pmid":"21441980","id":"PMC_21441980","title":"Phorbol-Ester Mediated Suppression of hASH1 Synthesis: Multiple Ways to Keep the Level Down.","date":"2011","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/21441980","citation_count":33,"is_preprint":false},{"pmid":"39264686","id":"PMC_39264686","title":"Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1.","date":"2024","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/39264686","citation_count":32,"is_preprint":false},{"pmid":"35366798","id":"PMC_35366798","title":"Elevated ASCL1 activity creates de novo regulatory elements associated with neuronal differentiation.","date":"2022","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/35366798","citation_count":32,"is_preprint":false},{"pmid":"34558659","id":"PMC_34558659","title":"Performance of DNA methylation analysis of ASCL1, LHX8, ST6GALNAC5, GHSR, ZIC1 and SST for the triage of HPV-positive women: Results from a Dutch primary HPV-based screening cohort.","date":"2021","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34558659","citation_count":32,"is_preprint":false},{"pmid":"21684625","id":"PMC_21684625","title":"Insights into the achaete-scute homolog-1 gene (hASH1) in normal and neoplastic human lung.","date":"2012","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/21684625","citation_count":29,"is_preprint":false},{"pmid":"29545540","id":"PMC_29545540","title":"Subcellular localisation modulates ubiquitylation and degradation of Ascl1.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29545540","citation_count":29,"is_preprint":false},{"pmid":"34712921","id":"PMC_34712921","title":"MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer.","date":"2021","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/34712921","citation_count":28,"is_preprint":false},{"pmid":"35149717","id":"PMC_35149717","title":"ASCL1 phosphorylation and ID2 upregulation are roadblocks to glioblastoma stem cell differentiation.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35149717","citation_count":28,"is_preprint":false},{"pmid":"34289357","id":"PMC_34289357","title":"Heterogeneity of neurons reprogrammed from spinal cord astrocytes by the proneural factors Ascl1 and Neurogenin2.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34289357","citation_count":28,"is_preprint":false},{"pmid":"37660160","id":"PMC_37660160","title":"Ascl1 and Ngn2 convert mouse embryonic stem cells to neurons via functionally distinct paths.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37660160","citation_count":28,"is_preprint":false},{"pmid":"20124469","id":"PMC_20124469","title":"ASCL1 regulates the expression of the CHRNA5/A3/B4 lung cancer susceptibility locus.","date":"2010","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/20124469","citation_count":28,"is_preprint":false},{"pmid":"39609428","id":"PMC_39609428","title":"Transcription factors ASCL1 and OLIG2 drive glioblastoma initiation and co-regulate tumor cell types and migration.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39609428","citation_count":27,"is_preprint":false},{"pmid":"37355053","id":"PMC_37355053","title":"ASCL1-mediated ferroptosis resistance enhances the progress of castration-resistant prostate cancer to neurosecretory prostate cancer.","date":"2023","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37355053","citation_count":27,"is_preprint":false},{"pmid":"32170367","id":"PMC_32170367","title":"Significance of achaete-scute complex homologue 1 (ASCL1) in pulmonary neuroendocrine carcinomas; RNA sequence analyses using small cell lung cancer cells and Ascl1-induced pulmonary neuroendocrine carcinoma cells.","date":"2020","source":"Histochemistry and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/32170367","citation_count":27,"is_preprint":false},{"pmid":"30121393","id":"PMC_30121393","title":"An Integrative Analysis of Transcriptome and Epigenome Features of ASCL1-Positive Lung Adenocarcinomas.","date":"2018","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30121393","citation_count":27,"is_preprint":false},{"pmid":"38039971","id":"PMC_38039971","title":"ASCL1 induces neurogenesis in human Müller glia.","date":"2023","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/38039971","citation_count":26,"is_preprint":false},{"pmid":"35194152","id":"PMC_35194152","title":"Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35194152","citation_count":26,"is_preprint":false},{"pmid":"38359163","id":"PMC_38359163","title":"ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.","date":"2024","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/38359163","citation_count":25,"is_preprint":false},{"pmid":"27863528","id":"PMC_27863528","title":"Oligodendrocyte development in the embryonic tuberal hypothalamus and the influence of Ascl1.","date":"2016","source":"Neural development","url":"https://pubmed.ncbi.nlm.nih.gov/27863528","citation_count":25,"is_preprint":false},{"pmid":"31212628","id":"PMC_31212628","title":"Inhibition of Glioma Development by ASCL1-Mediated Direct Neuronal Reprogramming.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31212628","citation_count":24,"is_preprint":false},{"pmid":"34143204","id":"PMC_34143204","title":"Initiation of Otx2 expression in the developing mouse retina requires a unique enhancer and either Ascl1 or Neurog2 activity.","date":"2021","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/34143204","citation_count":24,"is_preprint":false},{"pmid":"26596584","id":"PMC_26596584","title":"hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors.","date":"2015","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26596584","citation_count":23,"is_preprint":false},{"pmid":"11195458","id":"PMC_11195458","title":"Morphometric analysis of CC10-hASH1 transgenic mouse lung: a model for bronchiolization of alveoli and neuroendocrine carcinoma.","date":"2000","source":"Experimental lung research","url":"https://pubmed.ncbi.nlm.nih.gov/11195458","citation_count":23,"is_preprint":false},{"pmid":"32122989","id":"PMC_32122989","title":"Physical interactions between Gsx2 and Ascl1 balance progenitor expansion versus neurogenesis in the mouse lateral ganglionic eminence.","date":"2020","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/32122989","citation_count":23,"is_preprint":false},{"pmid":"34878841","id":"PMC_34878841","title":"Injury-induced ASCL1 expression orchestrates a transitory cell state required for repair of the neonatal cerebellum.","date":"2021","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/34878841","citation_count":22,"is_preprint":false},{"pmid":"32499571","id":"PMC_32499571","title":"ASCL1-regulated DARPP-32 and t-DARPP stimulate small cell lung cancer growth and neuroendocrine tumour cell proliferation.","date":"2020","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32499571","citation_count":22,"is_preprint":false},{"pmid":"16021468","id":"PMC_16021468","title":"Genetic association analyses of PHOX2B and ASCL1 in neuropsychiatric disorders: evidence for association of ASCL1 with Parkinson's disease.","date":"2005","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16021468","citation_count":22,"is_preprint":false},{"pmid":"31836808","id":"PMC_31836808","title":"hASH1 nuclear localization persists in neuroendocrine transdifferentiated prostate cancer cells, even upon reintroduction of androgen.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31836808","citation_count":21,"is_preprint":false},{"pmid":"29510143","id":"PMC_29510143","title":"Instructing neuronal identity during CNS development and astroglial-lineage reprogramming: Roles of NEUROG2 and ASCL1.","date":"2018","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/29510143","citation_count":21,"is_preprint":false},{"pmid":"36263020","id":"PMC_36263020","title":"The proneural transcription factor ASCL1 regulates cell proliferation and primes for differentiation in neuroblastoma.","date":"2022","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/36263020","citation_count":21,"is_preprint":false},{"pmid":"36715573","id":"PMC_36715573","title":"Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma.","date":"2023","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/36715573","citation_count":21,"is_preprint":false},{"pmid":"36061596","id":"PMC_36061596","title":"Ascl1 phospho-site mutations enhance neuronal conversion of adult cortical astrocytes in vivo.","date":"2022","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/36061596","citation_count":21,"is_preprint":false},{"pmid":"23481413","id":"PMC_23481413","title":"Heterochronic misexpression of Ascl1 in the Atoh7 retinal cell lineage blocks cell cycle exit.","date":"2013","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/23481413","citation_count":21,"is_preprint":false},{"pmid":"15272537","id":"PMC_15272537","title":"Human achaete-scute homologue (hASH1) mRNA level as a diagnostic marker to distinguish esthesioneuroblastoma from poorly differentiated tumors arising in the sinonasal tract.","date":"2004","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15272537","citation_count":21,"is_preprint":false},{"pmid":"35538066","id":"PMC_35538066","title":"Helicobacter pylori infection activates Wnt/β-catenin pathway to promote the occurrence of gastritis by upregulating ASCL1 and AQP5.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35538066","citation_count":21,"is_preprint":false},{"pmid":"35789143","id":"PMC_35789143","title":"ASCL1 regulates super-enhancer-associated miRNAs to define molecular subtypes of small cell lung cancer.","date":"2022","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/35789143","citation_count":20,"is_preprint":false},{"pmid":"35590427","id":"PMC_35590427","title":"Histone H3.3 K27M chromatin functions implicate a network of neurodevelopmental factors including ASCL1 and NEUROD1 in DIPG.","date":"2022","source":"Epigenetics & chromatin","url":"https://pubmed.ncbi.nlm.nih.gov/35590427","citation_count":20,"is_preprint":false},{"pmid":"21495212","id":"PMC_21495212","title":"Hes1/Hes5 gene inhibits differentiation via down-regulating Hash1 and promotes proliferation in cervical carcinoma cells.","date":"2010","source":"International journal of gynecological cancer : official journal of the International Gynecological Cancer Society","url":"https://pubmed.ncbi.nlm.nih.gov/21495212","citation_count":19,"is_preprint":false},{"pmid":"11464865","id":"PMC_11464865","title":"Downregulation of hASH1 is associated with the retinoic acid-induced differentiation of human neuroblastoma cell lines.","date":"2001","source":"Medical and pediatric oncology","url":"https://pubmed.ncbi.nlm.nih.gov/11464865","citation_count":19,"is_preprint":false},{"pmid":"29683222","id":"PMC_29683222","title":"ASCL1 regulates proliferation of NG2-glia in the embryonic and adult spinal cord.","date":"2018","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/29683222","citation_count":19,"is_preprint":false},{"pmid":"37552603","id":"PMC_37552603","title":"ASCL1 is activated downstream of the ROR2/CREB signaling pathway to support lineage plasticity in prostate cancer.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37552603","citation_count":18,"is_preprint":false},{"pmid":"36517551","id":"PMC_36517551","title":"Molecular features and evolutionary trajectory of ASCL1+ and NEUROD1+ SCLC cells.","date":"2022","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36517551","citation_count":18,"is_preprint":false},{"pmid":"28832532","id":"PMC_28832532","title":"The Potential of Targeting Brain Pathology with Ascl1/Mash1.","date":"2017","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/28832532","citation_count":18,"is_preprint":false},{"pmid":"35252201","id":"PMC_35252201","title":"Function of Proneural Genes Ascl1 and Asense in Neurogenesis: How Similar Are They?","date":"2022","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/35252201","citation_count":18,"is_preprint":false},{"pmid":"34931456","id":"PMC_34931456","title":"ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.","date":"2021","source":"Thoracic cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34931456","citation_count":18,"is_preprint":false},{"pmid":"30861584","id":"PMC_30861584","title":"Expression of ventral telencephalon transcription factors ASCL1 and DLX2 in the early fetal human cerebral cortex.","date":"2019","source":"Journal of anatomy","url":"https://pubmed.ncbi.nlm.nih.gov/30861584","citation_count":18,"is_preprint":false},{"pmid":"38233864","id":"PMC_38233864","title":"Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer.","date":"2024","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/38233864","citation_count":18,"is_preprint":false},{"pmid":"26700681","id":"PMC_26700681","title":"A novel role for Ascl1 in the regulation of mesendoderm formation via HDAC-dependent antagonism of VegT.","date":"2015","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/26700681","citation_count":18,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51405,"output_tokens":10377,"usd":0.154935,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21160,"output_tokens":6486,"usd":0.133975,"stage2_stop_reason":"end_turn"},"total_usd":0.28891,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"Ascl1 controls excitatory vs. inhibitory cell fate in spinal sensory interneurons by coordinately regulating Tlx3 expression (with Gsh1/2) during early neurogenesis and, at later stages, controlling Ptf1a expression in dIL(A) progenitors to promote inhibitory neuron differentiation while upregulating Notch signaling to ensure generation of dIL(B) excitatory neurons.\",\n      \"method\": \"Mouse genetic loss-of-function (Ascl1 knockout), genetic epistasis, in vivo analysis of transcription factor expression\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined cellular phenotype, epistasis analysis, replicated across multiple developmental time points in vivo\",\n      \"pmids\": [\"16715081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Ascl1 is required for the birth of central serotonergic neurons, functioning both as a proneural gene for the production of postmitotic neuronal precursors and as a determinant of the serotonergic phenotype by activating Gata3, Lmx1b, and Pet1 in parallel.\",\n      \"method\": \"Mouse Ascl1 knockout, analysis of 5-HT neuron production and serotonergic marker expression in vivo\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined cellular and molecular phenotype, multiple downstream targets characterized\",\n      \"pmids\": [\"15133515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Ascl1 marks sequentially generated lineage-restricted progenitors in the developing spinal cord: at E11 it identifies neuronal-restricted precursors that become dorsal horn neurons, and by E16 it identifies oligodendrocyte-restricted precursors. Ascl1-null spinal cord cells have diminished capacity for neuronal differentiation, with a subset retaining immature glial characteristics.\",\n      \"method\": \"Genetic fate mapping (Ascl1-CreER / conditional Cre-flox), Ascl1 knockout mouse, temporal inducible lineage tracing\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic fate mapping plus KO with defined cellular phenotypes across multiple time points\",\n      \"pmids\": [\"17166924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Ascl1 is required for oligodendrocyte development in the spinal cord: Ascl1-/- mice show deficiency in myelin-expressing oligodendrocyte differentiation; Ascl1 collaborates with Olig2 and Nkx2-2 to promote oligodendrocyte precursor differentiation, with the combinatorial action of Ascl1+Olig2 or Ascl1+Nkx2-2 required for full differentiation beyond OLP specification.\",\n      \"method\": \"Ascl1 knockout mouse, in vitro OLP culture studies, gain-of-function overexpression of Ascl1/Olig2/Nkx2-2 combinations\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO phenotype combined with gain-of-function and combinatorial factor analysis with defined molecular readouts\",\n      \"pmids\": [\"18287202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Ascl1 regulates Delta-like 3 (Dll3) expression in the neural tube by binding E-boxes in the conserved Dll3 proximal promoter. Distinct E-boxes confer enhancer or repressor properties; Ascl1 forms homodimers and Ascl1/Neurog2 heterodimers that bind specific E-box sites, sometimes requiring additional undefined factors for efficient DNA binding.\",\n      \"method\": \"Transgenic reporter mice (Dll3-GFP), E-box mutagenesis, chromatin immunoprecipitation (ChIP), in vitro DNA binding assays, genetic loss-of-function\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro DNA binding with mutagenesis, ChIP, transgenic reporter validation, and genetic KO, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"19389376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Ascl1 is present in progenitors of all glial and neuronal cell types arising from the cerebellar ventricular zone. Conditional deletion of Ascl1 in the cerebellum causes major decreases in three types of GABAergic interneurons and an imbalance of oligodendrocytes and astrocytes; Ptf1a functions with Ascl1 in generating interneurons and Purkinje cells (double-mutant epistasis).\",\n      \"method\": \"Genetic inducible fate mapping (Ascl1-CreER), conditional Ascl1 knockout, double-mutant (Ascl1/Ptf1a) analysis\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — fate mapping plus conditional KO plus epistasis analysis with defined cellular phenotypes\",\n      \"pmids\": [\"21795554\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"FOXO3 shares common genomic targets with ASCL1 in adult neural progenitor cells (NPCs); FOXO3-bound sites are enriched for bHLH motifs; FOXO3 inhibits ASCL1-dependent neurogenesis in NPCs and direct neuronal conversion in fibroblasts, and restrains neurogenesis in vivo.\",\n      \"method\": \"ChIP-seq (FOXO3 and ASCL1), chromatin landscape analysis, loss-of-function neurogenesis assays in NPCs and fibroblasts, in vivo neurogenesis assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide ChIP-seq for both factors plus functional KD/OE assays in vitro and in vivo, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"23891001\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Ascl1 is required for brain oligodendrogenesis during myelination and remyelination: Ascl1 positively regulates OPC specification from SVZ progenitors and the balance between OPC differentiation and proliferation in the neonatal cortex; remyelinating oligodendrocytes derive from Ascl1+ progenitors and Ascl1 is required for proper remyelination.\",\n      \"method\": \"Multiple genetic Ascl1 deletion strategies in cortical progenitors and OPCs, demyelination mouse models, analysis of human MS lesions\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic deletion approaches, in vivo demyelination model, and human tissue validation\",\n      \"pmids\": [\"23739972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ASCL1 alone is sufficient to generate functional induced neuronal (iN) cells from mouse and human fibroblasts and embryonic stem cells; ASCL1-induced single-factor neurons are predominantly excitatory, demonstrating ASCL1 is permissive but not deterministic for the inhibitory neuronal lineage.\",\n      \"method\": \"Forced expression of single transcription factor ASCL1 in MEFs and human fibroblasts/ESCs; electrophysiology, synaptic marker analysis, neuronal morphology assessment\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional reprogramming in multiple cell types with electrophysiological validation and synaptic characterization\",\n      \"pmids\": [\"25254342\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ASCL1 directly transcriptionally activates the RB1 gene via phosphorylation-dependent inactivation; this is reversible by CDK5 inhibition. ASCL1 targets include MYCL1, RET, SOX2, NFIB (oncogenic genes), and multiple NOTCH pathway genes including DLL3, as determined by ChIP-seq in SCLC.\",\n      \"method\": \"ChIP-seq, whole-genome microarray expression analysis, shRNA knockdown, CDK5 inhibition in vitro\",\n      \"journal\": \"Cell reports / PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq and expression analysis with functional validation in multiple SCLC cell lines, two independent papers\",\n      \"pmids\": [\"27452466\", \"25267614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Ascl1 alone is sufficient to convert dorsal midbrain astrocytes into functional induced neurons in vivo; GFAP-AAV-mediated Ascl1 expression converts astrocytes in dorsal midbrain, striatum, and somatosensory cortex of postnatal and adult mice into neurons that form synaptic inputs and outputs with existing neurons.\",\n      \"method\": \"GFAP-AAV viral delivery in postnatal and adult mice, morphological analysis, electrophysiology, synaptic connectivity tracing\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo conversion with functional electrophysiological and synaptic connectivity validation\",\n      \"pmids\": [\"26109658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Multi-site phosphorylation of Ascl1 at serine-proline motifs by CDKs inhibits its ability to induce differentiation of AVNA (anteroventral noradrenergic) cells; a phospho-mutant Ascl1 drives differentiation even when CDKs or MYCN are overexpressed, whereas wild-type Ascl1 is inhibited. This was shown in a Xenopus developmental model.\",\n      \"method\": \"Xenopus in vivo gain- and loss-of-function, phospho-mutant ASCL1 constructs, CDK overexpression, Xenopus AVNA cell differentiation assays\",\n      \"journal\": \"Disease models & mechanisms\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — phospho-site mutagenesis with in vivo functional readout, epistasis with CDKs/MYCN, single lab but multiple genetic manipulations\",\n      \"pmids\": [\"25786414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The NOTCH-ASCL1-RB-p53 signaling axis drives secondary SCLC: NOTCH inactivating mutations lead to ASCL1 activation; ASCL1 inactivates RB via phosphorylation (reversible by CDK5 inhibition); this pathway was experimentally verified in vitro and validated by genetic alterations in vivo.\",\n      \"method\": \"In vitro cell line experiments with CDK5 inhibition, NGS of clinical samples, IHC, FISH; pathway epistasis analysis\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — functional in vitro validation of ASCL1-dependent RB phosphorylation plus CDK5 inhibitor reversal, single lab\",\n      \"pmids\": [\"26340530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"EZH2 promotes SCLC progression by epigenetically silencing TGF-β type II receptor (TβRII), thereby suppressing the TGF-β-Smad-ASCL1 pathway; ASCL1 is a Smad-dependent transcriptional target of TGF-β signaling that induces cell survival in SCLC.\",\n      \"method\": \"TβRII overexpression in SCLC cells, TGF-β treatment, EZH2 functional analysis, in vitro growth/apoptosis assays, in vivo tumor formation\",\n      \"journal\": \"Cell discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — functional experiments with defined pathway epistasis and in vivo validation, single lab\",\n      \"pmids\": [\"27462425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ASCL1 functions as a pioneer factor in glioblastoma stem cells (GSCs), opening closed chromatin to activate a neurogenic gene expression program; ASCL1hi GSCs have latent capacity for terminal neuronal differentiation upon Notch inhibition, and increasing ASCL1 in ASCL1lo GSCs restores neuronal lineage potential, promotes differentiation, and attenuates tumorigenicity.\",\n      \"method\": \"ATAC-seq, ChIP-seq, Notch inhibition, ASCL1 overexpression in patient-derived GSCs, in vivo tumorigenicity assays, chromatin accessibility analysis\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pioneer factor activity demonstrated by chromatin opening assays (ATAC-seq) combined with functional tumorigenicity and differentiation assays in patient-derived cells\",\n      \"pmids\": [\"28712938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Subcellular localization modulates ASCL1 ubiquitylation and degradation: cytoplasmic ASCL1 harbors long ubiquitin chains and is targeted for proteasomal destruction via the E3 ligase Huwe1, with ubiquitin conjugated to lysines in the bHLH domain; chromatin-bound ASCL1 associates with short ubiquitin chains (on N-terminal or bHLH lysines, not mediated by Huwe1) and is not targeted for destruction.\",\n      \"method\": \"Subcellular fractionation, ubiquitylation assays, E3 ligase (Huwe1) knockdown/inhibition, site-directed mutagenesis of lysine residues\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — biochemical fractionation combined with mutagenesis, E3 ligase identification, and mechanistic dissection of two distinct ubiquitylation states\",\n      \"pmids\": [\"29545540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Proneural factors Ascl1 and Neurog2 induce different neuronal fates by binding largely different genomic sites; their divergent binding patterns are not determined by prior chromatin state but are distinguished by enrichment of specific E-box sequences reflecting DNA-binding domain preferences. Divergent binding results in distinct chromatin accessibility and enhancer activity profiles that differentially shape binding of downstream transcription factors.\",\n      \"method\": \"Direct neuronal programming of ESCs, ChIP-seq, ATAC-seq, comparative genomic binding analysis, E-box motif analysis\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP-seq and ATAC-seq with mechanistic follow-up identifying E-box specificity as the determinant of divergent binding, multiple orthogonal methods\",\n      \"pmids\": [\"31086315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"High Hes1 expression in quiescent adult neural stem cells continuously suppresses Ascl1, keeping cells quiescent; oscillatory Hes1 drives cyclic Ascl1 expression in active neural stem cells, promoting proliferation. Inactivation of Hes1-related genes upregulates Ascl1 and increases neurogenesis, causing NSC depletion; sustained Hes1 represses Ascl1 and maintains quiescence. Induction of Ascl1 oscillations (rather than sustained expression) activates NSCs.\",\n      \"method\": \"Hes1 conditional knockout in adult mouse brain, live imaging of oscillatory expression, Hes1 sustained overexpression, neurogenesis quantification in vivo\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic manipulations in vivo combined with live imaging to dissect oscillatory vs. sustained expression states\",\n      \"pmids\": [\"30862661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ASCL1 is a direct transcriptional target of LMO1 and MYCN in neuroblastoma; regulatory elements of ASCL1 are bound by LMO1, MYCN, and CRC transcription factors GATA3, HAND2, PHOX2B, TBX2, ISL1. ASCL1 is required for neuroblastoma cell growth and arrest of differentiation, and directly regulates expression of CRC genes.\",\n      \"method\": \"ChIP-seq, RNA-seq, ASCL1 knockdown functional assays in neuroblastoma cell lines\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq demonstrating direct binding of multiple upstream regulators at ASCL1 locus, functional KD with defined proliferation and differentiation phenotypes\",\n      \"pmids\": [\"31819055\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Physical interaction between Gsx2 homeodomain protein and the bHLH domain of Ascl1 interferes with Ascl1 DNA binding, inhibiting neurogenesis in LGE ventricular zone progenitors; Ascl1-Gsx2 interactions are enriched in LGE VZ progenitors while Ascl1-E-protein (Tcf3) interactions predominate in the SVZ.\",\n      \"method\": \"Luciferase transcriptional assays, protein-protein interaction (Co-IP/proximity ligation assay in tissue sections), DNA-binding assays, Ascl1 misexpression in dorsal progenitors, Gsx2/Ascl1 co-expression experiments\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct protein interaction demonstrated by proximity ligation in tissue, DNA binding interference shown biochemically, functional transcriptional assays, in vivo validation\",\n      \"pmids\": [\"32122989\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Ascl1 directly regulates a set of target genes during astrocyte-to-neuron conversion including Klf10 (neuritogenesis), Myt1/Myt1l (electrophysiological maturation), and Neurod4/Chd7 (conversion efficiency); ChIP-seq identified 107 genes whose regulatory regions are directly bound by ASCL1 during early conversion.\",\n      \"method\": \"RNA-seq, ChIP-seq, siRNA knockdown of individual targets during astrocyte-to-neuron conversion, electrophysiology, morphological analysis\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq combined with functional KD of individual direct targets with specific phenotypic readouts\",\n      \"pmids\": [\"33577795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ASCL1 represses a SOX9+/RUNX1/RUNX2 neural crest stem-like program in MYC-driven SCLC; ASCL1 loss in MYC-driven SCLC promotes emergence of a SOX9+ mesenchymal state and osteosarcoma/chondroid tumors, while promoting neuroendocrine fate and NKX2-1/FOXA2/INSM1 expression; ASCL1 also represses Hippo/Wnt/Notch developmental pathway genes.\",\n      \"method\": \"Genetically engineered mouse models (GEMMs), genetic ASCL1 depletion, RNA-seq, in vivo tumor analysis, human SCLC cell SOX9 expression analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic depletion in multiple GEMMs with defined tumor identity phenotypes and transcriptomic analysis\",\n      \"pmids\": [\"34016693\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ASCL1 complexes with NKX2-1 and PROX1 to co-regulate genes functioning in NOTCH signaling, catecholamine biosynthesis, and cell-cycle processes in ASCL1-high SCLC; ASCL1 depletion reduces expression of multiple DepMap-defined essential genes.\",\n      \"method\": \"ChIP-seq, ATAC-seq, super-enhancer analysis, ASCL1 knockdown, Co-immunoprecipitation/interaction analysis of ASCL1/NKX2-1/PROX1\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq demonstrating co-occupancy, protein complex identification, and KD functional analysis with defined gene expression targets\",\n      \"pmids\": [\"34466783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ASCL1 acts as a pioneer factor to open closed chromatin and as a non-pioneer remodeler at permissive chromatin during human neural differentiation; ASCL1 interacts with BAF SWI/SNF chromatin remodeling complexes primarily at non-pioneer targets, with codependent DNA binding and remodeling at a subset of ASCL1/SWI/SNF co-targets.\",\n      \"method\": \"Single-cell transcriptomics, ASCL1 knockout model, ATAC-seq, ChIP-seq, Co-IP of ASCL1 with BAF complex subunits, chromatin conformation analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO defining unbound state, ATAC-seq showing chromatin opening, Co-IP identifying SWI/SNF interaction, multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"36931659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Ascl1 possesses cross-lineage reprogramming potential; together with Mef2c, it drives efficient cardiac reprogramming. MEF2C shifts ASCL1 binding away from neuronal genes toward cardiac genes, guiding cooperative epigenetic and transcriptional activity.\",\n      \"method\": \"ChIP-seq, RNA-seq, direct cardiac reprogramming assays, comparison of ASCL1 binding in neuronal vs. cardiac reprogramming contexts\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide ChIP-seq demonstrating MEF2C-dependent binding shift plus functional reprogramming assays, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"36206732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Elevated ASCL1 activity in neuroblastoma cells creates numerous additional low-affinity binding sites beyond endogenous sites; multi-site phosphorylation of ASCL1 limits this additional binding; preventing phosphorylation (phospho-mutant) further increases genome-wide binding and gene activation, redirecting the transcriptome from proliferative neuroblast state toward neuronal differentiation.\",\n      \"method\": \"ASCL1 overexpression and phospho-mutant expression in neuroblastoma cells, ChIP-seq, RNA-seq, genome-wide binding site analysis\",\n      \"journal\": \"BMC genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq and RNA-seq comparing wild-type vs. phospho-mutant ASCL1 with functional transcriptomic readout, single lab multiple orthogonal methods\",\n      \"pmids\": [\"35366798\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ASCL1 acts as a driver of neuroendocrine lineage plasticity in prostate cancer via large-scale chromatin remodeling; ASCL1 motif is enriched in hyper-accessible chromatin regions after ARPI treatment; targeting ASCL1 switches neuroendocrine lineage back to luminal epithelial state via UHRF1/AMPK-mediated disruption of polycomb repressive complex-2.\",\n      \"method\": \"ATAC-seq, ChIP-seq, ASCL1 knockdown/overexpression, chromatin architecture analysis, UHRF1/AMPK pathway manipulation, in vivo tumor models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple chromatin assays, genetic manipulation of ASCL1 and downstream epigenetic machinery, in vivo validation\",\n      \"pmids\": [\"35477723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ASCL1 phospho-mutant (Ascl1-SA6, six serine-to-alanine substitutions at SP motifs) is more effective than wild-type Ascl1 at converting adult cortical astrocytes to neurons in vivo; Ascl1-SA6 more efficiently represses astrocytic markers SOX9 and GFAP, promotes dendritic arbor maturation, and transduced astrocytes exhibit neuronal electrophysiological responses (faster decay of evoked potentials).\",\n      \"method\": \"AAV delivery in adult mouse cerebral cortex, Rosa reporter mice, immunofluorescence, patch-clamp electrophysiology, ChR2 optogenetic stimulation\",\n      \"journal\": \"Frontiers in neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phospho-site mutagenesis combined with in vivo functional electrophysiological validation, multiple AAV/reporter combinations tested\",\n      \"pmids\": [\"36061596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ASCL1 phosphorylation at SP sites and upregulation of ID2 are barriers to ASCL1-driven differentiation in GBM stem cells; a phospho-mutant ASCL1 (non-phosphorylatable at SP sites) drives GBM cells to neuronal lineage and out of cell cycle more efficiently; the effect is further enhanced by deletion of ID2.\",\n      \"method\": \"Phospho-mutant ASCL1 overexpression in GBM stem cells, CRISPR-mediated ID2 deletion, cell cycle analysis, neuronal differentiation assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phospho-site mutagenesis combined with genetic deletion of inhibitor, functional differentiation and cell cycle readouts, single lab multiple methods\",\n      \"pmids\": [\"35149717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Ascl1 rapidly dismantles the pluripotency network during ESC-to-neuron conversion, while Ngn2 generates a neural stem cell-like intermediate via incomplete pluripotency network shutdown; Ascl1 relies more on Tcf7l1 for cell cycle exit (in Tcf7l1 KO, Ascl1 represses pluripotency genes but fails to exit cell cycle; overexpression of Cdkn1c restores cell cycle exit and neuronal generation).\",\n      \"method\": \"CRISPR-Cas9 KO screening, RNA-seq, ChIP-seq, direct ESC-to-neuron conversion, Cdkn1c overexpression rescue experiments\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide CRISPR screen with mechanistic follow-up via KO/rescue experiments and transcriptomic analysis\",\n      \"pmids\": [\"37660160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"EWS-WT1 oncoprotein directly activates ASCL1 transcription by binding the proximal ASCL1 promoter through multiple WT1-responsive elements; EWS-WT1 silencing in DSRCT cells reduces ASCL1 expression and cell viability.\",\n      \"method\": \"ChIP assay, luciferase reporter assays with ASCL1 promoter, EWS-WT1 knockdown/transgenic mouse, DSRCT cell functional assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and promoter reporter assays with functional KD validation, single lab\",\n      \"pmids\": [\"24934812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Gli2 directly binds multiple regulatory regions (promoter and enhancer) of the Ascl1 gene and activates its promoter in vitro; Gli2 upregulates Ascl1 to induce neurogenesis, and dominant-negative Gli2 significantly downregulates Ascl1 expression, causing delayed neurogenesis.\",\n      \"method\": \"ChIP assays, luciferase reporter assays with Ascl1 promoter, Gli2 overexpression and dominant-negative Gli2 in P19 cells\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter assay with dominant-negative functional validation, single lab in cell line model\",\n      \"pmids\": [\"21559470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ASCL1 regulates expression of the CHRNA5/A3/B4 nicotinic acetylcholine receptor gene cluster in SCLC; knockdown of ASCL1 specifically decreases alpha3 and beta4 subunit expression without affecting other nAChR genes, indicating a specific regulatory relationship.\",\n      \"method\": \"ASCL1 shRNA knockdown in SCLC and non-SCLC cells, qRT-PCR, in silico promoter analysis identifying ASCL1 binding sites\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — KD with specific gene expression readout, replicated in multiple cell lines, no direct binding demonstrated\",\n      \"pmids\": [\"20124469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ASCL1 regulates Wnt11 expression via H3K27 acetylation at the WNT11 gene enhancer region; ASCL1 knockdown downregulates Wnt11 in SCLC; Wnt11 in turn controls neuroendocrine differentiation, cell proliferation, and E-cadherin expression downstream of ASCL1, with AKT and p38 MAPK phosphorylation increased by Wnt11.\",\n      \"method\": \"ASCL1 transfection into A549 cells, ASCL1 knockdown in SCLC lines, ChIP for H3K27ac at WNT11 enhancer, WNT11 knockdown functional assays\",\n      \"journal\": \"Laboratory investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP showing epigenetic regulation combined with KD functional assays, single lab\",\n      \"pmids\": [\"31231131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Phorbol ester (PMA) suppresses hASH1 (ASCL1) synthesis via distinct sequential mechanisms: short-term inhibition through mRNA destabilization dependent mainly on protein kinase C activity; prolonged suppression (48h) through decreased ASCL1 promoter activity and inhibition of mRNA translation.\",\n      \"method\": \"Reporter gene assays (promoter-luciferase and UTR-luciferase), PKC inhibitor experiments, mRNA stability assays in neuroblastoma-derived Kelly cells\",\n      \"journal\": \"Frontiers in molecular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assays with UTR and promoter constructs combined with PKC inhibitor pharmacology, single lab\",\n      \"pmids\": [\"21441980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Maternal Ascl1 protein in Xenopus represses VegT-induced mesendoderm (but not Nodal-induced mesendoderm); a previously uncharacterized N-terminal domain of Ascl1 interacts with HDAC1 to inhibit mesendoderm gene expression via histone deacetylation at VegT target promoters; this N-terminal domain is dispensable for neurogenic function, indicating distinct mechanisms for different functions.\",\n      \"method\": \"Gain- and loss-of-function experiments in Xenopus, domain deletion mutants, HDAC interaction assay, HDAC inhibitor treatment, ChIP for histone acetylation at target gene promoters\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — domain mutagenesis, HDAC interaction demonstration, ChIP for histone marks, functional in vivo assays showing domain-specific mechanism\",\n      \"pmids\": [\"26700681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ROR2 receptor tyrosine kinase activates the ERK/CREB signaling pathway to modulate ASCL1 expression in prostate cancer; ROR2 upregulation following AR pathway inhibition feeds into lineage plasticity via ASCL1 activation.\",\n      \"method\": \"RTK screen, ROR2 knockdown/overexpression, ERK/CREB pathway inhibitor experiments, ASCL1 expression analysis in prostate cancer cells\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — RTK screen with functional validation via pathway inhibitors, single lab but multiple approaches to link ROR2/CREB to ASCL1\",\n      \"pmids\": [\"37552603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ASCL1 is required for neuroendocrine differentiation in prostate cancer in vivo; genetic loss of Ascl1 in RPM (Rb1-/-/Trp53-/-/Myc+) mouse prostate organoid allografts decreases NE identity and increases basal-like identity without affecting tumor incidence, growth, or metastasis.\",\n      \"method\": \"Genetically engineered mouse prostate organoids with Cre-induced Rb1/Trp53 loss and Myc overexpression, Ascl1 conditional genetic deletion, histopathology, immunofluorescence, scRNA-seq\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional genetic KO in in vivo allograft model with defined lineage identity phenotype and transcriptomic analysis\",\n      \"pmids\": [\"39264686\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ASCL1+ cells arise from KRT8+ luminal cells during neuroendocrine prostate cancer (NEPC) transition; Ascl1 loss before transplantation abrogates lineage plasticity, resulting in castration-sensitive adenocarcinomas, while Ascl1 deletion in established NEPC causes only transient regression.\",\n      \"method\": \"Multiplexed immunofluorescence, spatial transcriptomics, Ascl1 conditional deletion at different stages, in vivo mouse prostate organoid transplantation model\",\n      \"journal\": \"Nature cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — spatial transcriptomics and multiplexed IF for lineage tracing combined with stage-specific Ascl1 deletion revealing distinct functional requirements\",\n      \"pmids\": [\"39394434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SMAD4 competes with Myc to regulate ASCL1 transcription in NSCLC cells; SMAD4 deficiency accelerates SCLC transition by inducing neuroendocrine phenotype through increased ASCL1 transcription, independently of RB1 status in TP53-deficient cells.\",\n      \"method\": \"CRISPR-Cas9 SMAD4/RB1 knockout in HCC827 and A549-TP53-/- cells, Myc inhibitor treatment, in vitro and in vivo tumor models, mRNA and protein expression analysis\",\n      \"journal\": \"Cell communication and signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR KO with functional in vivo readout and Myc competition mechanism, single lab\",\n      \"pmids\": [\"38233864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ASCL1 confers drug tolerance to osimertinib in EGFR mutant lung cancer by initiating an epithelial-to-mesenchymal gene-expression program in permissive cellular contexts; this effect is context-specific and not observed in all tumor types.\",\n      \"method\": \"Patient-derived xenograft models, single-cell transcriptional profiling, osimertinib treatment to maximal regression, ASCL1 expression analysis in residual disease\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — scRNA-seq in PDX models identifying mechanistic transcriptional program, but ASCL1's causal role in EMT inferred rather than demonstrated by direct manipulation\",\n      \"pmids\": [\"38359163\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ASCL1 is a bHLH pioneer transcription factor that binds E-box sequences in open and closed chromatin (the latter via pioneer activity), interacts with the BAF SWI/SNF complex and with protein partners (Neurog2, Gsx2, NKX2-1, PROX1, HDAC1) to open chromatin and activate neurogenic/neuroendocrine gene programs; its activity is restrained by multi-site CDK-mediated serine-proline phosphorylation, which limits DNA binding and differentiation-promoting activity, while subcellular localization determines its ubiquitylation by Huwe1 and proteasomal degradation; upstream, its expression is oscillatorily controlled by Hes1 (which suppresses it to maintain quiescence), and it is directly activated by Gli2, LMO1/MYCN, EWS-WT1, and ROR2/CREB signaling, positioning ASCL1 as a context-dependent master regulator of neurogenesis, gliogenesis, and neuroendocrine lineage commitment in both normal development and cancer.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ASCL1 is a basic helix-loop-helix (bHLH) proneural transcription factor that acts as a context-dependent master regulator of neuronal, glial, and neuroendocrine lineage commitment in development and cancer [#1, #14]. It binds E-box sequences as homodimers or as heterodimers with Neurog2, and functions as a pioneer factor capable of opening closed chromatin to activate neurogenic gene programs; at permissive sites it acts as a non-pioneer remodeler, interacting with BAF SWI/SNF complexes for co-dependent DNA binding and remodeling [#4, #14, #23]. During neurogenesis ASCL1 specifies diverse fates—serotonergic neurons via Gata3/Lmx1b/Pet1, GABAergic interneurons, and oligodendrocytes in collaboration with Olig2 and Nkx2-2—and the choice between excitatory and inhibitory output is shaped by partners and downstream targets including Tlx3, Ptf1a, and Notch [#0, #1, #3, #5]. ASCL1 alone is sufficient to reprogram fibroblasts, ESCs, and astrocytes into functional neurons, dismantling the pluripotency network and driving cell-cycle exit through Tcf7l1/Cdkn1c, while co-expression with MEF2C redirects it toward cardiac fates [#8, #10, #24, #29]. Its activity is constrained at several levels: multi-site CDK-mediated serine-proline phosphorylation limits genome-wide DNA binding and differentiation-promoting activity, subcellular localization governs Huwe1-mediated ubiquitylation and proteasomal degradation, and protein partners such as Gsx2 and the inhibitor ID2 antagonize its function [#11, #15, #20, #28]. Upstream, ASCL1 expression is held in check by Hes1, whose sustained versus oscillatory expression gates neural stem cell quiescence versus activation [#17]. In cancer, ASCL1 drives neuroendocrine identity in small-cell lung cancer—complexing with NKX2-1 and PROX1 and activating NOTCH, RB1, and catecholamine biosynthesis targets—and mediates neuroendocrine lineage plasticity in prostate cancer through large-scale chromatin remodeling [#9, #21, #22, #26, #38]. A separable N-terminal domain recruits HDAC1 to repress mesendoderm genes, illustrating that ASCL1 deploys distinct activating and repressive mechanisms for different programs [#35].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Establishing that ASCL1 is not merely a generic proneural factor but a determinant of specific neurotransmitter identity answered how a single bHLH factor links cell-cycle exit to phenotype specification.\",\n      \"evidence\": \"Mouse Ascl1 knockout with analysis of serotonergic marker activation in vivo\",\n      \"pmids\": [\"15133515\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct binding of ASCL1 to Gata3/Lmx1b/Pet1 loci not shown\", \"Mechanism distinguishing proneural from phenotype-specifying functions undefined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defining how ASCL1 coordinately controls fate choices clarified that it can both promote inhibitory differentiation and, via Notch, ensure excitatory neuron generation, revealing combinatorial and feedback logic.\",\n      \"evidence\": \"Mouse knockout and genetic epistasis with Tlx3/Gsh and Ptf1a in spinal cord, plus inducible fate mapping\",\n      \"pmids\": [\"16715081\", \"17166924\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs. indirect regulation of Ptf1a/Tlx3 not fully resolved\", \"Temporal switch from neuronal to oligodendrocyte progenitor identity mechanistically unexplained\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showing ASCL1 cooperates combinatorially with Olig2 and Nkx2-2 extended its role beyond neurons into oligodendrocyte differentiation and gliogenesis.\",\n      \"evidence\": \"Ascl1 knockout plus gain-of-function combinatorial overexpression in OLP cultures\",\n      \"pmids\": [\"18287202\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physical interaction of ASCL1 with Olig2/Nkx2-2 not demonstrated\", \"Shared vs. distinct genomic targets unmapped\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Direct ChIP and E-box mutagenesis at the Dll3 promoter established ASCL1 as a sequence-specific DNA binder acting through homodimers and Neurog2 heterodimers, with E-boxes conferring either activation or repression.\",\n      \"evidence\": \"Transgenic reporter mice, E-box mutagenesis, ChIP, and in vitro DNA binding\",\n      \"pmids\": [\"19389376\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of additional factors required for efficient binding unknown\", \"Structural basis of enhancer vs. repressor E-box discrimination undefined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identifying FOXO3 as a co-binding factor that restrains ASCL1-dependent neurogenesis and the Hes1-ASCL1 relationship began mapping the upstream regulatory architecture governing ASCL1 output.\",\n      \"evidence\": \"ChIP-seq for FOXO3 and ASCL1 with loss-of-function neurogenesis assays in NPCs and fibroblasts\",\n      \"pmids\": [\"23891001\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FOXO3 acts by direct competition or recruitment unresolved\", \"Brain oligodendrogenesis role (PMID 23739972) mechanistically separate from binding studies\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrating that ASCL1 alone suffices to generate functional neurons from fibroblasts and ESCs established it as a deterministic reprogramming factor and a tool for lineage conversion.\",\n      \"evidence\": \"Single-factor forced expression with electrophysiology and synaptic characterization\",\n      \"pmids\": [\"25254342\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why single-factor neurons default to excitatory identity not explained\", \"Chromatin requirements for reprogramming competence not addressed here\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Connecting ASCL1 to cancer, work showed it directly activates RB1 in a phosphorylation-dependent manner and drives oncogenic and NOTCH target programs in SCLC, plus upstream activation by EWS-WT1.\",\n      \"evidence\": \"ChIP-seq, expression profiling, shRNA, CDK5 inhibition in SCLC; ChIP and reporter assays for EWS-WT1\",\n      \"pmids\": [\"27452466\", \"25267614\", \"24934812\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"EWS-WT1 link is Medium-confidence single lab\", \"Causal hierarchy among ASCL1 oncogenic targets not dissected\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defining multi-site CDK phosphorylation as an inhibitory switch answered how ASCL1's differentiation-promoting activity is held in check despite its presence in cycling progenitors.\",\n      \"evidence\": \"Xenopus phospho-mutant constructs with CDK/MYCN epistasis and AVNA differentiation assays\",\n      \"pmids\": [\"25786414\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the specific CDKs acting in each context not fully resolved\", \"Phosphatases reversing the modification unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Pathway-level studies placed ASCL1 within a NOTCH-ASCL1-RB-p53 axis and a TGF-β-Smad-ASCL1 survival pathway, situating it in cancer signaling networks.\",\n      \"evidence\": \"In vitro CDK5 inhibition, clinical NGS/IHC, and TβRII/EZH2/TGF-β manipulation in SCLC\",\n      \"pmids\": [\"26340530\", \"27462425\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Both are single-lab Medium-confidence\", \"Direct vs. indirect Smad regulation of the ASCL1 locus not established\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Direct demonstration of pioneer activity in glioblastoma stem cells showed ASCL1 opens closed chromatin to license a latent neuronal differentiation program suppressed by Notch.\",\n      \"evidence\": \"ATAC-seq, ChIP-seq, Notch inhibition, and ASCL1 overexpression in patient-derived GSCs with in vivo tumorigenicity\",\n      \"pmids\": [\"28712938\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular determinants of pioneer-competent sites not defined here\", \"Co-factors enabling chromatin opening unidentified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linking subcellular localization to ubiquitylation state identified Huwe1-mediated cytoplasmic degradation versus a stable chromatin-bound pool, adding post-translational control of ASCL1 abundance.\",\n      \"evidence\": \"Subcellular fractionation, ubiquitylation assays, Huwe1 knockdown, and lysine mutagenesis\",\n      \"pmids\": [\"29545540\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signals directing cytoplasmic vs. nuclear partitioning unknown\", \"Function of short chromatin-associated ubiquitin chains undefined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Comparative genomics resolved why ASCL1 and Neurog2 induce distinct fates—divergent binding driven by intrinsic E-box preference rather than prior chromatin state—clarifying the basis of bHLH binding specificity.\",\n      \"evidence\": \"Direct ESC programming with ChIP-seq, ATAC-seq, and E-box motif analysis\",\n      \"pmids\": [\"31086315\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"DNA-binding domain residues conferring preference not mapped\", \"Role of downstream factors in reinforcing divergence partially defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrating that oscillatory versus sustained Hes1 gates ASCL1 dynamics established the upstream timer controlling neural stem cell quiescence versus activation, and identified LMO1/MYCN as direct activators of ASCL1 in neuroblastoma.\",\n      \"evidence\": \"Hes1 conditional KO with live imaging in adult brain; ChIP-seq/RNA-seq with ASCL1 knockdown in neuroblastoma\",\n      \"pmids\": [\"30862661\", \"31819055\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ASCL1 protein level decodes oscillatory input mechanistically unresolved\", \"WNT11/CHRNA target regulation (Medium-confidence) less directly validated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identifying a direct Gsx2-bHLH interaction that blocks ASCL1 DNA binding revealed a partner-switch mechanism (Gsx2 in VZ vs. E-protein in SVZ) that spatially tunes neurogenic output.\",\n      \"evidence\": \"Proximity ligation in tissue, Co-IP, DNA-binding interference assays, and in vivo misexpression\",\n      \"pmids\": [\"32122989\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of Gsx2-bHLH contact not determined\", \"Whether other homeodomain factors act similarly unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"GEMM and complex studies defined ASCL1's repressive role restraining a SOX9 mesenchymal program and its complexing with NKX2-1/PROX1 to maintain neuroendocrine SCLC identity.\",\n      \"evidence\": \"Genetic ASCL1 depletion in GEMMs with RNA-seq; ChIP-seq, ATAC-seq, and Co-IP of ASCL1/NKX2-1/PROX1\",\n      \"pmids\": [\"34016693\", \"34466783\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of ASCL1-mediated repression of Hippo/Wnt/Notch genes unresolved\", \"Stoichiometry and architecture of the ASCL1/NKX2-1/PROX1 complex undefined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Mechanistic dissection separated ASCL1's pioneer and non-pioneer modes and identified BAF SWI/SNF as a partner at non-pioneer targets, and showed phosphorylation and ID2 act as differentiation barriers in neuroblastoma and GBM.\",\n      \"evidence\": \"scRNA-seq, ATAC-seq, ChIP-seq, ASCL1 KO and Co-IP with BAF subunits; phospho-mutant and ID2-deletion functional assays in NB/GBM\",\n      \"pmids\": [\"36931659\", \"35366798\", \"35149717\", \"36061596\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants selecting pioneer vs. non-pioneer engagement incompletely defined\", \"How phosphorylation restricts low-affinity site occupancy mechanistically unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Cross-lineage and cancer-plasticity studies showed MEF2C redirects ASCL1 to cardiac genes and that ASCL1 drives neuroendocrine prostate plasticity via UHRF1/AMPK-mediated PRC2 disruption.\",\n      \"evidence\": \"ChIP-seq/RNA-seq cardiac reprogramming; ATAC-seq/ChIP-seq with UHRF1/AMPK manipulation and in vivo prostate tumor models\",\n      \"pmids\": [\"36206732\", \"35477723\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How MEF2C physically retargets ASCL1 binding undefined\", \"Direct vs. indirect connection between ASCL1 and PRC2 disruption not fully resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defining the divergent reprogramming logic of ASCL1 (rapid pluripotency dismantling, Tcf7l1/Cdkn1c-dependent cell-cycle exit) clarified the molecular steps by which it overrides existing cell identity, and identified ROR2/ERK/CREB as an upstream activator in prostate cancer.\",\n      \"evidence\": \"CRISPR KO screen with RNA-seq/ChIP-seq and Cdkn1c rescue; RTK screen with pathway inhibitors in prostate cancer\",\n      \"pmids\": [\"37660160\", \"37552603\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Tcf7l1 dependency is direct or via downstream effectors not fully resolved\", \"ROR2/CREB-to-ASCL1 link is Medium-confidence single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Stage-specific genetic studies established ASCL1 as required for initiating but not always maintaining neuroendocrine prostate plasticity, defined SMAD4-Myc competition over ASCL1 transcription, and linked ASCL1 to drug tolerance via an EMT program.\",\n      \"evidence\": \"Conditional Ascl1 deletion at different stages in prostate organoid allografts with scRNA-seq/spatial transcriptomics; CRISPR SMAD4/RB1 KO; PDX scRNA-seq under osimertinib\",\n      \"pmids\": [\"39264686\", \"39394434\", \"38233864\", \"38359163\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why established NEPC becomes ASCL1-independent unexplained\", \"EMT/drug-tolerance role (Medium-confidence) inferred rather than directly manipulated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ASCL1 integrates phosphorylation state, partner availability, and chromatin context to switch between pioneering, non-pioneering, activating, and repressive modes at the level of structure and recruitment remains unresolved.\",\n      \"evidence\": null,\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural model of ASCL1 on pioneer-competent nucleosomal DNA\", \"Rules dictating activator vs. repressor output at individual E-boxes undefined\", \"Phosphatases and full kinase repertoire controlling the phospho-switch unidentified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 4, 9, 14, 18]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [4, 16, 20]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [14, 23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [15, 23]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [15]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [4, 14, 23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 1, 3, 5, 8]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [4, 9, 18, 22]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [14, 23, 26]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [9, 21, 22, 26, 38]}\n    ],\n    \"complexes\": [\"BAF (SWI/SNF) complex\", \"ASCL1/NKX2-1/PROX1 complex\"],\n    \"partners\": [\"NEUROG2\", \"GSX2\", \"NKX2-1\", \"PROX1\", \"HDAC1\", \"MEF2C\", \"OLIG2\", \"ID2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}